**Antagonism of PP2A is an independent and conserved
function of HIV-1 Vif and causes cell cycle arrest**

Sara Marelli^{1,2}, James C Williamson^{1,2}, Anna V Protasio^{1,2}, Adi Naamati^{1,2}, Edward JD
Greenwood^{1,2}, Janet E Deane^{3,4}, Paul J Lehner^{1,2}, Nicholas J Matheson^{1,2,*}

1. Department of Medicine, University of Cambridge, UK

2. Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID),
University of Cambridge, UK

3. Department of Clinical Neuroscience, University of Cambridge, UK

4. Cambridge Institute for Medical Research (CIMR), University of Cambridge, UK

*Correspondence: njm25@cam.ac.uk.

14 **Abstract**

15 The seminal description of the cellular restriction factor APOBEC3G and its antagonism by
16 HIV-1 Vif has underpinned two decades of research on the host-virus interaction. We
17 recently reported that HIV-1 Vif is also able to degrade the PPP2R5 family of regulatory
18 subunits of key cellular phosphatase PP2A (PPP2R5A-E; Greenwood et al., 2016; Naamati
19 et al., 2019). We now identify amino acid polymorphisms at positions 31 and 128 of HIV-1 Vif
20 which selectively regulate the degradation of PPP2R5 family proteins. These residues
21 covary across HIV-1 viruses *in vivo*, favouring depletion of PPP2R5A-E. Through analysis of
22 point mutants and naturally occurring Vif variants, we further show that degradation of
23 PPP2R5 family subunits is both necessary and sufficient for Vif-dependent G2/M cell cycle
24 arrest. Antagonism of PP2A by HIV-1 Vif is therefore independent of APOBEC3 family
25 proteins, and regulates cell cycle progression in HIV-infected cells.

26 **Introduction**

27 The canonical function of HIV-1 Vif is to recruit the cellular restriction factor APOBEC3G for
28 CUL5 E3 ligase and ubiquitin-proteasome-dependent degradation in infected cells,
29 preventing APOBEC3G encapsidation and enhancing virion infectivity (Conticello et al.,
30 2003; Kobayashi et al., 2005; Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2002;
31 Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003). This interaction is very likely to be
32 important *in vivo*, because the ability of Vif to antagonise APOBEC3G and its homologues is
33 broadly conserved across lentiviral phylogeny, and has driven co-evolution of the
34 mammalian APOBEC3 family (Compton et al., 2013; Nakano et al., 2017).

35 The other cell biological phenotype associated with Vif in multiple studies is the induction of
36 G2/M cell cycle arrest (DeHart et al., 2008; Evans et al., 2018; Izumi et al., 2010; Sakai et
37 al., 2006; Wang et al., 2007; Zhao et al., 2015). Vif-dependent cell cycle arrest does not
38 require expression of APOBEC3 family proteins, but is reliant on lysine-48 ubiquitination and
39 the same CUL5 E3 ligase complex recruited by Vif to deplete APOBEC3G (DeHart et al.,
40 2008). It has therefore been suspected to reflect ubiquitination and degradation of an
41 unknown cellular factor involved in cell cycle progression (DeHart et al., 2008). Why only
42 certain HIV-1 Vif variants mediate this effect (Evans et al., 2018; Zhao et al., 2015), and how
43 widely conserved it is across the lentiviral lineage, have remained unclear.

44 We have recently discovered that, in addition to APOBEC3 family proteins, Vif is also able to
45 degrade the B56 family of regulatory subunits of the ubiquitous heterotrimeric serine-
46 threonine phosphatase PP2A (PPP2R5A-E) in HIV-1-infected CEM-T4 T cells (Greenwood
47 et al., 2016) and primary human CD4⁺ T cells (Naamati et al., 2019). Together with PP1,
48 PP2A is one of the major cellular serine-threonine phosphatases (Nasa and Kettenbach,
49 2018). Specificity of the PP2A holoenzyme is determined by the bound regulatory subunit,
50 and targets of PP2A-B56 have been implicated in a host of cellular processes, including the

51 regulation of mitotic kinases and cell cycle progression (Foley et al., 2011; Grallert et al.,
52 2015; Vallardi et al., 2019; Yang and Phiel, 2010).

53 The ability of Vif to degrade PPP2R5 subunits (illustrated for PPP2R5D in **Figure 1A**) is
54 shared by Vif variants from diverse primate and non-primate lentiviruses (Greenwood et al.,
55 2016), suggesting a beneficial effect on viral replication *in vivo*. In theory, however, depletion
56 of PPP2R5A-E could be dependent on or secondary to the phylogenetically conserved ability
57 of Vif to antagonise APOBEC3 family proteins. To demonstrate that these functions are
58 autonomous and have therefore been independently selected, we now screen a library of
59 rationally designed Vif point mutants, and identify amino acid substitutions at residues 31
60 and 128 which clearly separate APOBEC3 and PPP2R5 family protein depletion. We further
61 show that antagonism of PP2A explains the ability of Vif to cause cell cycle arrest, and that
62 this requires efficient depletion of all PPP2R5 family subunits. Naturally occurring
63 polymorphisms of residues 31 and 128 correlate with the ability of HIV-1 Vif variants to
64 cause cell cycle arrest, and reveal evidence of selection pressure for PPP2R5A-E depletion
65 *in vivo*.

66 **Results**

67 **Flow cytometric screen identifies mutations in HIV-1 Vif which separate PPP2R5B and** 68 **APOBEC3G depletion**

69 To determine whether antagonism of PPP2R5 and APOBEC3 family proteins are
70 independent functions of Vif, we first used the published structure of the Vif-CUL5 complex
71 (Guo et al., 2014) to construct a library of 34 HIV-1 NL4-3 Vif variants with point mutations in
72 solvent-exposed residues, focussing predominantly on regions distant from known
73 APOBEC3 family protein interaction interfaces (**Figure 1B** and **Figure 1–figure supplement**
74 **1A**, residues highlighted in yellow). None of these mutations is predicted to cause protein
75 misfolding, nor interfere with the interactions between Vif and other members of the Vif-
76 CUL5 E3 ligase complex (CBF- β , CUL5, ELOB and ELOC).

77 Amongst the five PPP2R5 family subunits, we previously showed that depletion of PPP2R5B
78 is most conserved across Vif variants from HIV-1/2 and the non-human primate lentiviruses
79 (Greenwood et al., 2016). We therefore transfected our library into HEK 293T cells (293Ts)
80 stably expressing HA-tagged PPP2R5B or APOBEC3G, and used flow cytometry to quantify
81 PPP2R5B and APOBEC3G depletion by each Vif variant (**Figure 1–figure supplement 1B-**
82 **C** and **Figure 1–figure supplement 2A-C**). As well as indicating preserved APOBEC3
83 family substrate recruitment, the ability to deplete APOBEC3G served as a control for
84 unanticipated effects on Vif expression or stability, or assembly of the Vif-CUL5 complex.

85 We discovered several Vif mutants to be defective for PPP2R5B depletion (**Figure 1C**). Vif
86 protein expression levels were similar (**Figure 1–figure supplement 3**), but some mutations
87 affected residues already known to be required for depletion of APOBEC3G (K26, Y44,
88 W70) (Letko et al., 2015) or APOBEC3C/F (R15) (Letko et al., 2015; Nakashima et al., 2016)
89 (**Figure 1D** and **Figure 1–figure supplement 2C**). Conversely, Vif variants with mutations in
90 residues Y30/I31, R33/K34 and I128 were defective for PPP2R5B depletion, retained the
91 ability to antagonise APOBEC3G, and had not been implicated in APOBEC3C/F depletion.

92 These residues are grouped in three similarly orientated patches on the Vif surface (**Figure**
93 **1B**, residues highlighted in red). Aiming to identify Vif variants specifically defective for
94 PPP2R5 subunit depletion, we therefore focused on mutations in residues I128, I31 and
95 R33/K34 for further evaluation, including representatives from each patch.

96 **Residues 128 and 31 of HIV-1 Vif differentially regulate APOBEC3 and PPP2R5 family** 97 **protein depletion**

98 As well as APOBEC3G, other APOBEC3 family members (such as APOBEC3F and
99 APOBEC3H haplotype II) are also able to restrict HIV replication (Feng et al., 2014), and Vif
100 recruits different APOBEC3 family members for degradation using distinct binding surfaces
101 (Binka et al., 2012b; Chen et al., 2009; Dang et al., 2009; Gaddis et al., 2003; Harris and
102 Anderson, 2016; He et al., 2008; Letko et al., 2015; Mehle et al., 2007; Nakashima et al.,
103 2016; Ooms et al., 2016; Richards et al., 2015; Russell and Pathak, 2007; Simon et al.,
104 2005a; Yamashita et al., 2008). In addition, Vif variants from HIV-1/2 and the non-human
105 primate lentiviruses differ in their abilities to deplete different PPP2R5 family subunits
106 (Greenwood et al., 2016). We therefore sought to determine whether the mutations we found
107 to separate depletion of PPP2R5B and APOBEC3G have similar effects on other family
108 members.

109 First, we tested the ability of Vif mutants lacking the ability to deplete PPP2R5B to deplete
110 HA-tagged APOBEC3F in 293Ts, similar to our initial flow cytometry screen (**Figure 1–**
111 **figure supplement 4A-C**). As previously reported (Letko et al., 2015; Nakashima et al.,
112 2016), mutation of R15 resulted in loss of activity against APOBEC3F. The RK33/34AA
113 mutant was also partially impaired, but other mutants retained full activity against
114 APOBEC3F. APOBEC3H haplotype II was not examined, because wildtype NL4-3 Vif (on
115 which our Vif mutant library was based) is unable to deplete this APOBEC3 family member
116 (Binka et al., 2012a; Ooms et al., 2013; Zhao et al., 2015).

To avoid the possibility of over-expression artefacts, we next focussed on endogenous APOBEC3 and PPP2R5 family proteins expressed in CEM-T4 T cells (CEM-T4s). These cells were transduced with the panel of I31, I128 and R33/K34 Vif mutants found in our flow cytometry screens to be specifically defective for PPP2R5B depletion, together with a Y44 mutant (also defective for APOBEC3G depletion) to serve as a control.

Levels of an indicative PPP2R5 subunit for which a reliable antibody is available (PPP2R5D, as in **Figure 1A**) were then measured by immunoblot (**Figure 2A**). As expected WT Vif was able to fully deplete PPP2R5D (lane 3). Conversely, mutations in residues I128, I31, R33/K34 and Y44 all restored PPP2R5D levels (lanes 4-9). Interestingly, the I128A (lane 4) and Y44A (lane 9) mutations only showed a partial rescue, suggesting a differential effect on different PPP2R5 subunits (PPP2R5B vs PPP2R5D). In addition, mutations in residues R33/K34 (lanes 7-8) were associated with lower levels of Vif expression (**Figure 2A**).

Validated antibodies capable of detecting and differentiating endogenous levels of all APOBEC3 and PPP2R5 family proteins are not available. We therefore evaluated the activity of a similar panel of Vif mutants using a tandem mass tag (TMT)-based functional proteomic approach (**Figure 2B**). CEM-T4 cells were transduced with different Vif mutants at a multiplicity of infection (MOI) of 3 (range 94.1-98.7% transduced cells), then subjected to whole cell proteome analysis after a further 48 hr.

In total, we identified 8,781 proteins (**Figure 2–source data 1**), including all 5 PPP2R5 family subunits (PPP2R5A/B/C/D/E) and 5 out of 7 APOBEC3 family members (B/C/D/F/G; not A/H). This concurs with previous data suggesting that APOBEC3A is restricted to myeloid cells (Berger et al., 2011; Koning et al., 2009; Peng et al., 2007; Refsland et al., 2010), and neither APOBEC3A nor APOBEC3H are expressed in CCRF-CEM cell lines at the mRNA level (Refsland et al., 2010). APOBEC3B is not antagonised by Vif (Doehle et al., 2005; Greenwood et al., 2016; Hultquist et al., 2011; Naamati et al., 2019), and is therefore not considered further.

As expected, all Vif mutants tested were defective for PPP2R5B depletion, and the Y44A mutant was also defective for APOBEC3G depletion (**Figure 2C-D**). In addition, and consistent with our immunoblot analysis (**Figure 2A**), substitutions of I128 led to loss of activity against PPP2R5A, with relatively preserved activity against PPP2R5C-E. Conversely, substitution of I31 led to a reciprocal pattern, with loss of activity against PPP2R5C-E, but relatively preserved activity against PPP2R5A. Substitutions of R33/K34 led to loss of activity against all PPP2R5 subunits, but were again associated with lower levels of Vif expression (**Figure 2-figure supplement 1**), and accompanied by partial loss of activity against APOBEC3 family proteins, particularly APOBEC3F (mirroring our flow cytometry data, **Figure 1-figure supplement 4A-C**). In conclusion, therefore, mutations in residues 128 and 31 separate PPP2R5 and APOBEC3 family depletion without affecting Vif stability, and differentially regulate the 5 PPP2R5 family members.

Depletion of PPP2R5 family subunits is necessary for Vif-dependent cell cycle arrest

We previously showed that expression of Vif results in extensive remodelling of the phosphoproteome in HIV-infected cells, including activation of the aurora kinases AURKA and AURKB, effects we attributed to PP2A antagonism (Greenwood et al., 2016; Naamati et al., 2019). As expected, transduction of CEM-T4s with WT Vif resulted in increased AURKA/B T loop phosphorylation (**Figure 3A**, lane 3). Conversely, Vif mutants with impaired ability to antagonise PPP2R5 family subunits were unable to trigger AURKA/B phosphorylation (**Figure 3A**, lanes 4-7).

Together with APOBEC3 family antagonism, it has been known for >10 years that certain Vif variants (including NL4-3 Vif) are also able to induce G2/M cell cycle arrest, and that this is dependent on CUL5 E3 ligase recruitment and the ubiquitin-proteasome system (DeHart et al., 2008; Evans et al., 2018; Izumi et al., 2010; Sakai et al., 2006; Wang et al., 2007; Zhao et al., 2015). The Vif substrate explaining this phenomenon has, however, remained obscure.

Since both PP2A-B56 (PP2A heterotrimers incorporating one of the B56 family of regulatory subunits, PPP2R5A-E) and aurora kinases are required to coordinate mitotic progression (Foley et al., 2011; Grallert et al., 2015; Nasa and Kettenbach, 2018; Vallardi et al., 2019), we hypothesised that depletion of PPP2R5 family subunits may explain Vif-dependent cell cycle arrest, and that Vif mutants with impaired activity against PPP2R5 family subunits may also be defective for this phenotype. To test this hypothesis, we first interrogated our proteomic dataset. As predicted, WT Vif led to elevated levels of cyclin B1, indicative of G2/M arrest (**Figure 3B**). Conversely, elevation of cyclin B1 was reduced or abolished in the presence of Vif mutants lacking the ability to deplete PPP2R5 family subunits.

To confirm this result and formally evaluate cell cycle progression, we measured DNA content of CEM-T4s 48 hrs after transduction with WT or mutant Vif variants. Again, WT Vif, but not Vif mutants lacking the ability to deplete PPP2R5 subunits, caused G2/M arrest (**Figure 3C-D**). As a control, 2 other Vif mutants (F39A and D61A) which retained the ability to antagonise PPP2RB (**Figure 1–figure supplement 2A**), also retained the ability to cause cell cycle arrest (**Figure 3–figure supplement 1**).

In addition to APOBEC3 and PPP2R5 family proteins, we recently showed that NL4-3 Vif is also able to target FMR1 and DPH7 (Naamati et al., 2019). Both I128A and I128D point mutants retain the ability to deplete these proteins (**Figure 3–figure supplement 2**), but are unable to mediate cell cycle arrest. Depletion of PPP2R5 family subunits, but not other Vif substrates, is therefore required for Vif-dependent aurora kinase activation and G2/M cell cycle arrest.

Depletion of PPP2R5 family subunits is sufficient to cause cell cycle arrest

Consistent with PPP2R5A-E depletion by Vif, inhibition of PP2A with okadaic acid causes G2/M cell cycle arrest in CEM-T4s (**Figure 4–figure supplement 1A**). However, whilst relatively specific for PP2A over other cellular phosphatases, okadaic acid does not distinguish individual PPP2R5 family subunits, nor separate PP2A-B56 activity from the

activity of other PP2A heterotrimers incorporating regulatory subunits from different families (Swingle et al., 2007).

Since Vif-dependent cell cycle arrest is abrogated by point mutations which rescue quite distinct PPP2R5 subunits (compare **Figure 2C** and **Figure 3D**), some functional redundancy between the different B56 family members seems likely. Indeed, all PPP2R5 family subunits share a well conserved substrate-binding pocket (Hertz et al., 2016; Wang et al., 2016), and previous studies have suggested functional equivalence in mitosis (Foley et al., 2011; Lee et al., 2017). Conversely, another more recent study suggested topological restriction of PPP2R5 subunit activity within cells (Vallardi et al., 2019). We therefore sought to test the requirement for different PPP2R5 subunits for cell cycle progression using combinatorial knockdowns. To permit this approach, we used HeLa cells (HeLas) as a model system.

First, we confirmed that, as in CEM-T4s, expression of WT NL4-3 Vif in HeLas causes cell cycle arrest (**Figure 4–figure supplement 1B**). Likewise, mRNA expression levels of individual PPP2R5 subunits were determined by quantitative real-time PCR (qRT-PCR), and found to be similar between cell types, with PPP2R5B much lower than other subunits (**Figure 4–figure supplement 2A**). Next, we transfected HeLas with siRNA targeting individual PPP2R5 subunits, or a pool of siRNA simultaneously targeting all subunits (same total siRNA concentration). Strikingly, we only observed cell cycle arrest when all subunits were knocked down together (**Figure 4A-B**, “pool”). Indistinguishable results were seen for 2 independent panels of PPP2R5 family subunit siRNAs, and efficiency of siRNA knockdown was confirmed by qRT-PCR (**Figure 4– figure supplement 2B**).

To confirm that knockdown of all PPP2R5 subunits is necessary for cell cycle arrest, we repeated the experiment using pools of siRNA targeting 4 out of 5 PPP2R5 subunits (“minus one”). Again, and with the exception of PPP2R5B, cell cycle arrest was only observed when all subunits were knocked down together (**Figure 4C-D**). Interestingly, near-identical results were previously reported from RPE1 cells (Lee et al., 2017).

That depletion of PPP2R5B is neither sufficient (**Figure 4A-B**) nor required (**Figure 4C-D**) in this setting may reflect low expression of PPP2R5B (**Figure 4-figure supplement 2A**), consistent with previous protein-level data from HeLas (Geiger et al., 2012). To test this hypothesis, we generated HeLa cells expressing exogenous PPP2R5B at similar levels to other PPP2R5 subunits (**Figure 4-figure supplement 2C**). As predicted, transfection of a pool of siRNA targeting PPP2R5A, C D and E (but not B) caused cell cycle arrest in wildtype HeLas, but not HeLas over-expressing PPP2R5B (**Figure 4-figure supplement 2D-E**, compare with **Figure 4C-D**).

Finally, knockdown of FMR1 and DPH7 (**Figure 4-figure supplement 3**) did not cause cell cycle arrest. Taken together, these observations therefore explain why efficient depletion of all PPP2R5 subunits is required to cause cell cycle arrest, and why Vif variants with impaired activity against any PPP2R5 subunit are defective for this phenotype.

Naturally occurring Vif variants phenocopy I31 and I128 point mutants

The ability to cause G2/M cell cycle arrest is known to vary between naturally occurring HIV-1 Vif variants from clade B viruses (such as NL4-3 and HXB2), as well as viruses from other clades (Evans et al., 2018; Zhao et al., 2015). We therefore examined conservation of residues 31, 33/34 and 128 across 2,171 clade B HIV-1 Vif sequences available from the Los Alamos National Laboratory Web Alignments database (**Figure 5A**). Similar results were obtained when 3,412 Vif sequences from all (any clade, including B) non-recombinant HIV-1 M groups viruses were considered (**Figure 5-figure supplement 1**).

Interestingly, residues 31 (I or V), 33 (K, G or R) and 128 (I or R, or less commonly L or V) all showed obvious polymorphism, with NL4-3 Vif encoding the commonest amino acids at positions 31 (I) and 128 (I), and the second commonest amino acid at position 33 (R). We therefore evaluated each of the common polymorphisms as single point mutations on a background of NL4-3 Vif using our flow cytometric screen. Conservative substitutions in positions 31 and 128 partially impaired the ability of NL4-3 Vif to deplete PPP2R5B (I31V,

247 I128V and I128L), whereas I128R resulted in more marked impairment (**Figure 5B**).
248 Likewise, R33K, but not R33G, was well tolerated.

249 To evaluate these polymorphisms in their natural context, we tested Vif variants from two
250 further clade B HIV-1 viruses in our flow cytometric assay: the HIV-1 reference strain HXB2
251 (encoding 31V, 33G and 128I), and the macrophage-tropic patient isolate YU2 (encoding
252 31I, 33G and 128R). As a control, we also included a Vif variant from the clade B transmitted
253 founder virus CH470 (encoding 31I, 33K and 128I, similar to NL4-3 Vif) (**Figure 5C**).
254 Consistent with the observed substitutions at residues 31, 33 and 128, HXB2 and YU2 Vif
255 variants were markedly impaired for PPP2R5B depletion, whereas CH470 Vif was at least as
256 active as NL4-3 Vif (**Figure 5D**). Depletion of APOBEC3G was preserved in each case
257 (**Figure 5–figure supplement 2**).

258 To further assess the function of these variants against other APOBEC3 and PPP2R5 family
259 members, we again adopted a TMT-based functional proteomic approach (**Figure 6A**). As
260 well as HXB2, YU2 and CH470 Vif variants, we included NL4-3 Vif variants with
261 corresponding point mutations at positions 31 and 128 (I31V and I128R). In practice, since
262 residue 127 is also polymorphic, and residues 127 and 128 together overlap a critical HIV
263 splicing silencer (Madsen and Stoltzfus, 2005), we combined I128R and R127Y mutations
264 (RI127/128YR, as found in YU2 Vif and detailed in **Figure 6–figure supplement 1**). Finally,
265 to test the combinatorial effect of mutations in residues 31 and 128, we included an NL4-3
266 Vif variant encoding both I31A and RI127/128YR (Vif AYR). CEM-T4 cells were transduced
267 with the panel of Vif variants at an MOI of 3 (range 93.9-98.4% transduced cells), then
268 subjected to whole cell proteome analysis after a further 48 hr.

269 In this experiment, we identified 8,265 proteins (**Figure 6–source data 1**), including 4 out of
270 5 PPP2R5 family subunits (A/C/D/E) and 4 out of 7 APOBEC3 family members (B/C/D/G).
271 As expected, CH470 Vif remained fully active against all PPP2R5 (**Figure 6B**) and
272 APOBEC3 (**Figure 6C**) family subunits. Conversely, both YU2 and (in particular) HXB2 Vif
273 variants were selectively impaired for PPP2R5 depletion (**Figure 6B**). In each case, the

differential pattern of PPP2R5 family subunit depletion mirrored the effects of corresponding point mutations of residue 31 (HXB2 and NL4-3 I31V, mainly affecting PPP2R5C-E) or 128 (YU2 and NL4-3 R1127/128YR, mainly affecting PPP2R5A). Interestingly, whilst qualitatively similar to the I31A, I128A and I128D Vif mutants evaluated earlier, Vif variants with these naturally occurring polymorphisms were less severely impaired (compare **Figure 2C** with **Figure 6B**).

As a functional readout, we tested the ability of the same panel of Vif variants to cause cell cycle arrest. Consistent with previous reports (Evans et al., 2018; Zhao et al., 2015) and correlating with their impaired activity against PPP2R5 family subunits, HXB2 and NL4-3 I31V Vif variants were unable to cause cell cycle arrest (**Figure 6D** and **Figure 6-figure supplement 2**). Similarly, the potency of YU2 and NL4-3 R1127/128YR Vif variants was greatly reduced, but not abolished. Naturally occurring polymorphisms at residues 31 and 128 therefore modulate the ability of Vif to deplete PPP2R5 family subunits, and explain why some HIV-1 Vif variants are unable to cause cell cycle arrest.

Combined I31 and I128 mutations abolish PPP2R5 family subunit depletion and rarely occur in nature

Unlike individual mutations of residues 31 or 128, combined I31A and R1127/128YR mutations in NL4-3 Vif (Vif AYR) completely abolished the depletion of all PPP2R5 family subunits in our proteomic analysis (**Figure 6B**), without affecting the depletion of APOBEC3 family proteins (**Figure 6C**). Since PPP2R5B and APOBEC3F were not quantitated in the proteomic experiment, we tested the ability of Vif AYR to deplete these subunits by flow cytometry in 293Ts, including APOBEC3G as a control (**Figure 6-figure supplement 3A-B**). As expected, Vif AYR was able to deplete APOBEC3F and APOBEC3G but not PPP2R5B, and failed to cause cell cycle arrest (**Figure 6D**).

We next sought to confirm these results in the context of viral infection by introducing the same mutations into the NL4-3-based HIV-AFMACS molecular clone (Naamati et al., 2019).

This Env-deficient (single round) reporter virus encodes a SBP-ΔLNGFR cell surface streptavidin-binding affinity tag, allowing facile one-step selection of infected cells with streptavidin-conjugated magnetic beads (Antibody-Free Magnetic Cell Sorting, AFMACS) (Matheson et al., 2014). To enable analysis of cell cycle without confounding by Vpr, a Vpr-deficient (ΔVpr) background was used.

To assess the function of Vif AYR against APOBEC3 and PPP2R5 family members during viral infection, we first adopted a TMT-based functional proteomic approach to compare mock-infected cells with cells infected with ΔVpr-Vif WT, ΔVpr-ΔVif or ΔVpr-Vif AYR viruses (**Figure 7A**). CEM-T4s were infected at an MOI of 0.5 (range 29.3-48.7% infected cells), purified using AFMACS after 48 hr (range 93.3-96.6% infected cells, **Figure 7-figure supplement 1A-B**), then subjected to whole cell proteome analysis.

In this experiment, we identified 6,297 proteins (**Figure 7-source data 1**), including 4 out of 5 PPP2R5 family subunits (A/C/D/E) but only 1 out of 7 APOBEC3 family member (C). As expected, ΔVpr-Vif WT virus (**Figure 7B**, left panel) but not ΔVpr-ΔVif virus (**Figure 7B**, middle panel) was able to deplete both APOBEC3C and PPP2R5 family proteins. Conversely, ΔVpr-Vif AYR virus (**Figure 7B**, right panel) retained the ability to deplete APOBEC3C, but was completely inactive against PPP2R5 family proteins. As a control, the Nef and Vpu target CD4 was similarly downregulated by each virus (Guy et al., 1987; Willey et al., 1992). To confirm a functional effect on PP2A, we then used these viruses to infect CEM-T4 T cells, and measured their effect on cell cycle progression. Again, only ΔVpr-Vif WT virus, but not ΔVpr-ΔVif or ΔVpr-Vif AYR viruses, was able to induce G2/M cell cycle arrest (**Figure 7C**). A similar effect was observed in HIV-infected primary human CD4+ T cells (**Figure 7-figure supplement 2A-B**).

If the ability of Vif to antagonise PP2A is maintained by selection pressure *in vivo*, combinations of unfavourable (less active against PPP2R5A-E) mutations in residues 31 and 128 (abolishing all PPP2R5 family subunit depletion) should be rare amongst naturally occurring HIV-1 Vif variants. Furthermore, if effects on viral fitness are synergistic, such

combinations should occur less frequently than predicted by chance. We therefore examined covariance of polymorphisms of residues 31 and 128 across the clade B HIV-1 Vif sequences available from the Los Alamos National Laboratory Web Alignments database (**Figure 7D**; same 2,171 sequences as **Figure 5A**).

Amongst these sequences, 21.8% encode 31V (less active) and 33.6% encode R128 (less active). By chance, combinations of 31V and 128R would therefore be expected in 7.3% of sequences. Conversely, this combination is observed in only 5.8% of sequences. Whilst this difference appears modest, the association between these polymorphisms is highly statistically significant ($p=0.0003$, Fisher's exact test, **Figure 7-figure supplement 3A**, left panel). We observed similar, significant under-representation when we limited our analysis to clade B viruses encoding combinations of 31I/V and 128I/R (**Figure 7-figure supplement 3A**, right panel), or extended it to include Vif sequences from all (any clade, including B) non-recombinant HIV-1 M groups viruses (**Figure 7-figure supplement 3B-C**; same 3,412 sequences as **Figure 5-figure supplement 1**).

To distinguish functional covariance of these residues from background linkage disequilibrium (co-inheritance of polymorphisms from a common ancestor), we constructed phylogenetic trees of all Vif variants based on Vif (**Figure 7E**) or Nef, Gag or Env (**Figure 7-figure supplement 4A**). Regardless of the viral protein used, viruses encoding different combinations of 31/128 polymorphisms were scattered throughout the phylogeny, with no obvious founder effect. Again, similar results were seen when we extended our analysis to include Vif sequences from all (any clade, including B) non-recombinant HIV-1 M groups viruses (**Figure 7-figure supplement 4B**).

Taken together, these data therefore provide evidence of a functional interaction between residues 31/128, and suggest significant *in vivo* selection pressure to maintain the ability of Vif to antagonise PP2A.

Discussion

The study of cellular proteins and processes targeted by HIV has provided critical insights into the host-virus interaction. Typically, these targets have been identified piecemeal, using candidate approaches. In contrast, we have recently adopted unbiased proteomic approaches to identify novel substrates of HIV accessory proteins (Greenwood et al., 2016; Greenwood et al., 2019; Matheson et al., 2015; Naamati et al., 2019). A key challenge is now to determine the biological significance of these targets for HIV-infected cells: both *whether* they are important, and *why* they are important.

In this study, we sought to address these questions for Vif targets PPP2R5A-E. By demonstrating that depletion of PPP2R5 family subunits by Vif is separable from targeting of APOBEC3 family proteins, we formally prove that PP2A antagonism is neither required for, nor an epiphenomenon of, APOBEC3 family protein depletion. Combined with evidence of conservation across HIV-1 viruses and the broader lentiviral lineage (Greenwood et al., 2016), these observations provide strong genetic evidence for the importance of PPP2R5 depletion by Vif *in vivo*.

Strikingly, the critical residues for PPP2R5 depletion identified in our screen included several previously determined to be important for Vif-dependent cell cycle arrest in other, independent studies (31, 33, 44) (DeHart et al., 2008; Zhao et al., 2015). As well as residues required for CUL5 complex assembly (114 and 145), several additional residues (14, 36, 48 and 40) were implicated in the same studies. Amongst these, a K36A point mutant showed an intermediate effect on PPP2R5B depletion in our screen (**Figure 1—figure supplement 2A**). The other residues were not tested, because we focussed on regions of Vif not known to be important for depletion of APOBEC3 family proteins, and residues with solvent-exposed side chains unlikely to lead to structural disruption.

We were initially puzzled because some Vif point mutants were markedly impaired in their ability to cause cell cycle arrest, yet retained the ability to deplete at least some PPP2R5

family subunits. Furthermore, the ability of Vif to cause cell cycle arrest did not appear to correlate with depletion of any one, specific PPP2R5 subunit. In fact, because efficient depletion of all PPP2R5 subunits is required to halt cell cycle progression, these are not paradoxes at all. This same model also suggests explanations for two related phenomena.

First, expression of HIV-1 Vif in mouse or COS cells results in depletion of PPP2R5D, but does not cause cell cycle arrest (Evans et al., 2018). As with Vif point mutants and naturally occurring variants in human cells, it seems likely that another PPP2R5 subunit escapes depletion in these species-mismatched cells. Second, we previously found the ability of Vif to antagonise at least some PPP2R5 subunits to be widely conserved (Greenwood et al., 2016), but the ability to cause cell cycle arrest is variable amongst HIV-1 Vif variants (Evans et al., 2018; Zhao et al., 2015). Since efficient depletion of all expressed PPP2R5 subunits is required to cause cell cycle arrest, escape of even a single subunit allows cell cycle to progress.

Amongst all HIV-1 Vif sequences analysed here, the commonest single combination or residues at positions 31 and 128 was 31I/128I, accounting for approximately 30% of Vif variants. Most of these sequences also encode 33R or 33K and, like NL4-3 and CH470 Vif, are therefore expected to efficiently degrade PPP2R5A-E, and cause cell cycle arrest. Conversely, only approximately 5% encode 31V/128R, and are therefore expected to be severely impaired for PPP2R5A-E degradation. It is likely that most of the remaining Vif variants, like YU2 and HXB2, are active against at least some PPP2R5 family members, but may be variably attenuated in their ability to cause cell cycle arrest. Interestingly, naturally occurring Vif variants have also been shown to exhibit a spectrum of activity against APOBEC3 family proteins, including variants which fail to neutralise one or more APOBEC3 family proteins (Binka et al., 2012a; Iwabu et al., 2010; Mulder et al., 2008; Simon et al., 2005b).

Mechanistically, hyperphosphorylation of aurora kinase substrates is expected to contribute significantly to Vif-dependent cell cycle arrest (Foley et al., 2011). Nonetheless, PP2A is a

“master regulator” of cell cycle (Wlodarchak and Xing, 2016), and depletion of PPP2R5A-E by Vif causes widespread remodelling of the phosphoproteome, implying activation of multiple kinases (Greenwood et al., 2016). Consistent with this, Vif-dependent cell cycle arrest was previously shown to require TP53 (Izumi et al., 2010), and several studies have identified upstream regulation of TP53 by PP2A in different systems (Ajay et al., 2010; Li et al., 2002; Yang and Phiel, 2010).

Many RNA and DNA viruses cause and are thought to benefit from cell cycle arrest (Bagga and Bouchard, 2014). In HIV infection, G2/M cell cycle arrest was first attributed to Vpr (He et al., 1995; Jowett et al., 1995; Rogel et al., 1995), which remains better known for this function. Early studies suggested a positive effect of G2/M arrest on transcription from the HIV-1 LTR (Goh et al., 1998; Gummuluru and Emerman, 1999), but more recent results have raised the possibility that cell cycle arrest may be secondary to another Vpr-dependent process, such as antagonism of innate immunity (Laguette et al., 2014). Nonetheless, targeting of the same cell biological process by multiple viral accessory proteins is strong *a priori* evidence of biological importance *in vivo*.

Functional redundancy with Vpr may also help explain why Vif-dependent cell cycle arrest is not more strictly conserved across naturally occurring HIV-1 Vif variants. In addition, key polymorphic residues which regulate PPP2R5 antagonism may be subject to balancing selection pressures. First, the requirement to maintain the Exonic Splicing Silencer of Vpr (ESSV) at the RNA level limits the sequence variability tolerated at position 128 (Madsen and Stoltzfus, 2005). Second, polymorphisms at position 31 also regulate antagonism of APOBEC3H (Zhao et al., 2015). Indeed, at least in some cases, the abilities of Vif to antagonise APOBEC3H and cause cell cycle arrest were found to be mutually exclusive.

Vif-dependent cell cycle arrest correlates with viral cytopathicity (Evans et al., 2018; Sakai et al., 2006), and was reported to enhance HIV-1 replication *in vitro* in a previous study using chimeric HXB2/NL4-3 Vif variants (Izumi et al., 2010). Classic experiments comparing WT and Vif-deficient viruses in permissive cells often examined HXB2 (Gabuzda et al., 1992) or

432 YU2 (Gaddis et al., 2003) viruses. Since these Vif variants are shown here to be attenuated
433 in their activity against different PPP2R5 subunits, manifested by a reduced ability to cause
434 cell cycle arrest, it is likely that these studies failed to fully capture the effects of PP2A
435 antagonism on viral infection.

436 As importantly, the ability to assess APOBEC3-independent effects of Vif on viral fitness *in*
437 *vitro* has hitherto been limited to comparisons between WT and Vif-deficient viruses on an
438 APOBEC3-negative background, such as the CEM-SS cell line. In contrast, the point
439 mutants identified in this study maintain the ability to antagonise APOBEC3 family proteins,
440 and will therefore allow the assessment of Vif-dependent PP2A antagonism by the
441 community in a full range of cell types, including primary and myeloid cells, as well as
442 providing a mechanistic framework to interpret the results.

443 Materials and Methods

444 Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
cell line (human)	CEM-T4 T cells (CEM-T4s)	NIH AIDS Reagent Program	Cat. #: 117	Also known as CEM CD4+ cells
cell line (human)	THP-1 cells (THP-1s)	NIH AIDS Reagent Program	Cat. #: 9942	Used for cDNA library generation
cell line (human)	HeLa cells (HeLas)	Lehner laboratory stocks	RRID: CVCL_0030	
cell line (human)	HEK 293T cells (293Ts)	Lehner laboratory stocks	RRID: CVCL_0063	
antibody	Mouse monoclonal BV421-conjugated anti-CD4	BioLegend	Cat. #: 317434	Flow cytometry (1:50)
antibody	Mouse monoclonal PE-conjugated anti-CD4	BD Biosciences	Cat. #: 561843	Flow cytometry (1:50)
antibody	Mouse monoclonal AF647-conjugated anti-LNGFR	BioLegend	Cat. #: 345114	Flow cytometry (1:50)
antibody	Mouse monoclonal FITC-conjugated anti-LNGFR	BioLegend	Cat. #: 345103	Flow cytometry (1:50)
antibody	Mouse monoclonal BV421-conjugated anti CD4	BioLegend	Cat. #: 317434	Flow cytometry (1:50)
antibody	Mouse monoclonal DyLight 650-conjugated anti-HA tag	abcam	Cat. #: ab117515	Flow cytometry (1:400)
antibody	Rabbit monoclonal anti-PPP2R5D	abcam	Cat. #: ab188323	Immunoblot (1:5,000)
antibody	Mouse monoclonal anti-HIV-1 Vif	NIH AIDS Reagent Program	Cat. #: 6459	Immunoblot (1:2,500)
antibody	Rabbit polyclonal anti-FMR1 (FMRP)	Cell Signalling Technology	Cat. #: 4317	Immunoblot (1:1,000)
antibody	Rabbit polyclonal anti-DPH7	Atlas Antibodies	Cat. #: HPA022911	Immunoblot (1:1,000)
antibody	Mouse monoclonal anti- β -actin	Sigma	Cat. #: A5316	Immunoblot (1:20,000)
antibody	Mouse monoclonal anti-p97 (VCP)	Abcam	Cat. # ab11433	Immunoblot (1:10,000)
antibody	Rabbit polyclonal anti-total AURKB	Cell Signalling Technology	Cat. #: 3094	Immunoblot (1:500)
antibody	Rabbit monoclonal anti-phospho-AURK	Cell Signalling Technology	Cat. #: 2914	Immunoblot (1:500)
antibody	Rabbit polyclonal anti-GFP	Thermo Scientific	Cat. #: A-11122	Immunoblot (1:2,500)
recombinant DNA reagent	pHRSIN-SE-P2A-SBP- Δ LNGFR-W	(Matheson et al., 2014)	N/A	Used as a control and to express codon optimised Vif variants
recombinant DNA reagent	pHRSIN-SE-W-pSV40-puro	(van den Boomen et al., 2014)	N/A	Used as a control

recombinant DNA reagent	pHRSIN-S-W-pGK-puro	(Greenwood et al., 2016)	N/A	Used to express HA-tagged PPP2R5B, APOBEC3F and APOBEC3G
recombinant DNA reagent	HIV-AFMACS	(Naamati et al., 2019)	GenBank: MK435310.1	pNL4-3-ΔEnv-Nef-P2A-SBP-ΔLNGFR proviral construct
recombinant DNA reagent	V245 pCEP-4HA B56alpha	Addgene	Cat. #: 14532	Standard for quantification of PPP2R5A mRNA
recombinant DNA reagent	V245 pCEP-4HA B56beta	Addgene	Cat. #: 14533	Standard for quantification of PPP2R5B mRNA
recombinant DNA reagent	V245 pCEP-4HA B56gamma1	Addgene	Cat. #: 14534	Standard for quantification of PPP2R5C mRNA
recombinant DNA reagent	V245 pCEP-4HA B56delta	Addgene	Cat. #: 14536	Standard for quantification of PPP2R5D mRNA
recombinant DNA reagent	V245 pCEP-4HA B56epsilon	Addgene	Cat. #: 14537	Standard for quantification of PPP2R5E mRNA
recombinant DNA reagent	TBP cDNA clone: IRATp970C11110D	Source Bioscience	GenBank: BC110341.1	Standard for quantification of TBP mRNA
commercial assay or kit	NEBuilder HiFi DNA Assembly Cloning Kit	NEB	Cat. #: E5520S	
commercial assay or kit	Fugene 6 Transfection Reagent	Promega	Cat. #E2691	
commercial assay or kit	Lipofectamine RNAiMAX Transfection Reagent	Invitrogen	Cat. #: 18080044	
chemical compound, drug	Lenti-X Concentrator	Clontech	Cat. #: 631232	
commercial assay or kit	Dynabeads Biotin Binder	Invitrogen	Cat. #: 11047	
commercial assay or kit	Dynabeads Untouched Human CD4 T Cells kit	Invitrogen	Cat. #: 11346D	
commercial assay or kit	Dynabeads Human T-Activator CD3/CD28	Gibco	Cat. #: 11132D	
commercial assay or kit	S-Trap micro MS Sample Preparation Kit	Protifi	Cat. #: C02-micro	
commercial assay or kit	TMT10plex Isobaric Label Reagent Set	Thermo Scientific	Cat. #: 90110	
commercial assay or kit	Superscript III First-Strand Synthesis System	Invitrogen	Cat. #: 18080051	
software, algorithm	PyMOL Molecular Graphics System, Version 2.0	Schrödinger	RRID:SCR_006054	https://www.schrodinger.com/pymol
software, algorithm	Proteome Discoverer 2.1	Thermo Scientific	RRID:SCR_014477	
software, algorithm	R v.3.5.3	(R Core Team, 2019)	RRID:SCR_001905	https://www.R-project.org/
software, algorithm	limma	(Ritchie et al., 2015)	RRID:SCR_010943	https://bioconductor.org/packages/limma/
software, algorithm	WebLogo	(Crooks et al., 2004)	RRID:SCR_010236	http://weblogo.berkeley.edu
software, algorithm	seqinr	(Charif and Lobry, 2007)	N/A	https://cran.r-project.org/web/packages/seqinr/
software, algorithm	ggplot2	(Wickham, 2009)	RRID:SCR_014601	https://ggplot2.tidyverse.org

software, algorithm	ggtree	(Yu et al., 2018)	N/A	https://bioconductor.org/packages/release/bioc/html/ggtree.html
software, algorithm	Clustal Omega	(Sievers and Higgins, 2014)	RRID:SCR_001591	https://www.ebi.ac.uk/Tools/msa/clustalo/
software, algorithm	Prism 7.0	GraphPad	RRID:SCR_002798	

445

446 **General cell culture**

447 CEM-T4 T cells (Foley et al., 1965) and THP-1 cells (Wu et al., 2004) were obtained directly
448 (< 1yr) from the AIDS Reagent Program, Division of AIDS, NIAD, NIH (Dr J. P. Jacobs, and
449 Drs L. Wu and V. N. KewalRamani, respectively), and cultured at a density of 5×10^5 to 2×10^6
450 cells/ml in RPMI supplemented with 10% FCS, 100units/ml penicillin and 0.1 mg/ml
451 streptomycin at 37 °C in 5% CO₂. HeLa cells and HEK 293T cells (authenticated by STR
452 profiling (Menzies et al., 2018; Miles et al., 2017)) were obtained from Lehner laboratory
453 stocks and cultured in DMEM supplemented with 10% fetal calf serum (FCS), 100 units/ml
454 penicillin and 0.1 mg/ml streptomycin at 37 °C in 5% CO₂. All cells were regularly screened
455 and confirmed to be mycoplasma negative (Lonza MycoAlert).

456 **Primary cell isolation and culture**

457 Primary human CD4⁺ T cells were isolated from peripheral blood by density gradient
458 centrifugation over Lympholyte-H (Cedarlane Laboratories) and negative selection using the
459 Dynabeads Untouched Human CD4 T Cells kit (Invitrogen) according to the manufacturer's
460 instructions. Purity was assessed by flow cytometry for CD3 and CD4 and routinely found to
461 be ≥95%. Cells were activated using Dynabeads Human T-Activator CD3/CD28 beads
462 (Invitrogen) according to the manufacturer's instructions and cultured in RPMI supplemented
463 with 10% FCS, 30U/ml recombinant human IL-2 (PeproTech), 100units/ml penicillin and
464 0.1mg/ml streptomycin at 37°C in 5% CO₂.

465 **Ethics statement**

Ethical permission for this study was granted by the University of Cambridge Human Biology Research Ethics Committee (HBREC.2017.20). Written informed consent was obtained from all volunteers prior to providing blood samples.

Vectors for transgene expression

Sequences for Vif variants from NL4-3 (AF324493.2) , HXB2 (K03455.1), YU2 (GenBank: M93258.1) and CH470 (JX972238-JX972249) viruses were obtained from GenBank. The CH470 transmitted founder (TF) Vif sequence was inferred as previously described (Fenton-May et al., 2013; Liu et al., 2013; Parrish et al., 2013).

For co-expression of codon optimised Vif variants with EGFP, gBlocks (IDT) encoding NL4-3, HXB2, YU2 or CH470 Vif were incorporated into pHRSIN-SE-P2A-SBP-ΔLNGFR-W (Matheson et al., 2014) in place of SBP-ΔLNGFR by Gibson assembly between XhoI/KpnI sites (generating pHRSIN-SE-P2A-Vif-W vectors). In these vectors, Vif variants are expressed from the *Friend spleen focus-forming virus* (SFFV) promoter as EGFP-P2A-Vif, downstream of EGFP and a 'self-cleaving' *Porcine teschovirus-1* 2A (P2A) peptide.

Complete sequences for all gBlocks are included in **Supplementary file 1** (Codon-optimised Vif variants synthesised as gBlocks). Codon optimisation was conducted using the IDT codon optimisation tool, and sequences were verified by Sanger sequencing (Source BioScience).

The parental vector (in which EGFP and the SBP-ΔLNGFR cell surface selection marker are expressed from the SFFV promoter as EGFP-SBP-ΔLNGFR) was used here as a control. Where indicated, pHRSIN-SE-W-pSV40-puro (in which EGFP is expressed from the SFFV promoter as a single transgene) was used as an alternative control (van den Boomen et al., 2014).

To generate stable 293T cell lines for our flow cytometric screen, N-terminal 4xHA-tagged PPP2R5B and C-terminal 4xHA-tagged APOBEC3G were expressed using pHRSIN-S-W-pGK-puro exactly as previously described (Greenwood et al, 2016). HeLas stably expressing

exogenous PPP2R5B were generated using the same construct. C-terminal 4xHA-tagged APOBEC3F was amplified by PCR from a cDNA library generated from THP-1s using the Superscript III First-Strand Synthesis System (Invitrogen) with Oligo(dT) (Invitrogen), and also expressed using pHRSIN-S-W-pGK puro. The complete sequence is included in **Supplementary file 1** (C-terminal 4xHA-tagged APOBEC3F coding sequence in pHRSIN-S-W-pGK puro), and was verified by Sanger sequencing (Source BioScience).

Vif mutant library construction

To generate a library of Vif point mutants, a PCR and Gibson assembly-based approach was used to modify codon-optimised NL4-3 Vif directly in pHRSIN-SE-P2A-Vif-W (**Figure 1–figure supplement 1A**).

Briefly, forward and reverse primers encoding each point mutation were designed with ~15 bp fully complementary flanking sequences. These mutation-specific primers were used in pairwise PCR reactions in conjunction with common primers complementary to the vector backbone, which was cut between XhoI/KpnI sites. The two PCR products were then assembled into the vector using the NEBuilder HiFi DNA Assembly Master Mix (NEB).

Sequences for all primers used are tabulated in **Supplementary file 1** (PCR primers for Vif mutant library construction). All sequences were verified by Sanger sequencing (Source BioScience).

HIV-1 molecular clones

HIV-AFMACS (pNL4-3-ΔEnv-Nef-P2A-SBP-ΔLNGFR; GenBank: MK435310.1) has been previously described (Naamati et al., 2019). To introduce mutations in the native NL4-3 Vif coding sequence, the same PCR and Gibson assembly-based approach developed for Vif mutant library construction was used, cutting the vector backbone between AgeI/SalI sites. Where indicated, multiple mutations were introduced sequentially.

To generate Δ Vpr-Vif WT virus (lacking Vpr expression, but encoding WT Vif), a silent mutation was introduced into Vif codon 173 (AGA>AGG; both encoding Arg), eliminating the Vpr start codon in the +2 reading frame. Additional point mutations were introduced to generate Δ Vpr-Vif AYR virus (lacking Vpr expression, but encoding Vif with I31A and R127Y/I128R mutations) and Δ Vpr- Δ Vif virus (lacking Vpr expression, and encoding two premature stop codons after the final in-frame start codon in the Vif open reading frame).

Final Vif coding sequences for each virus are included in **Supplementary file 1** (Vif coding sequences in HIV-AFMACS viruses). Sequences were verified by Sanger sequencing (Source BioScience).

Transient transfection

For the flow cytometric screen, 293T cells stably expressing HA-tagged PPP2R5B or APOBEC3G were transfected with 200 ng/well control or Vif expression vector in 24-well plates using FuGENE 6 (Promega). After 36 hr, cells were harvested with trypsin-EDTA and analysed by flow cytometry.

siRNA transfection

For RNAi-mediated knockdown, HeLa cells were transfected with custom siRNA duplexes (Sigma) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.

Briefly, 2×10^5 cells/well were seeded in 6-well plates 24 hr prior to transfection with a total of 50 pmol/well siRNA (individual or pooled). Knockdown was verified by real-time PCR or immunoblot 24 hr post-transfection, and cells were re-seeded prior to cell cycle analysis 48 hr post-transfection (target 50% confluency).

All siRNA target sequences used are tabulated in **Supplementary file 1** (Target sequences for RNAi). Cells not subjected to knockdown were transfected with MISSION siRNA Universal Negative Control #1 (Sigma) at equivalent concentrations.

541 **Viral stocks**

542 VSVg-pseudotyped lentivector stocks were generated by co-transfection of 293Ts with
543 pHRSIN-based lentivector, p8.91 and pMD.G at a ratio of 2:1:1 (μ g) DNA and a
544 DNA:FuGENE 6 ratio of 1 μ g:3 μ l. Media was changed the next day and viral supernatants
545 harvested and filtered (0.45 μ m) at 48 hr prior to concentration with Lenti-X Concentrator
546 (Clontech) and storage at -80 °C.

547 VSVg-pseudotyped HIV-AFMACS viral stocks were generated by co-transfection of 293Ts
548 with HIV-AFMACS molecular clones and pMD.G at a ratio of 9:1 (μ g) DNA and a
549 DNA:FuGENE 6 ratio of 1 μ g:6 μ l. Viral supernatants were harvested, filtered, concentrated
550 and stored as per pHRSIN-based lentivector stocks.

551 Lentivector/viral stocks were titrated by transduction/infection of known numbers of relevant
552 target cells with known volumes of stocks under standard experimental conditions, followed
553 by flow cytometry for EGFP (GFP-expressing lentivectors) or SBP- Δ LNGFR and CD4 (HIV-
554 AFMACS viruses) at 48 hr to identify the fraction of transduced/infected cells (f) containing at
555 least one transcriptionally active provirus (EGFP positive or SBP- Δ LNGFR positive/CD4
556 low). The number of transducing/infectious units present was then calculated by assuming a
557 Poisson distribution (where $f = 1 - e^{-\text{MOI}}$). Typically, a dilution series of each stock was tested,
558 and titre determined by linear regression of $-\ln(1-f)$ on volume of stock.

559 **Transductions and infections**

560 Primary human CD4+ T cells, CEM-T4s, HeLas and 293Ts were transduced or infected by
561 spinoculation at 800 g for 1 hr in a non-refrigerated benchtop centrifuge in complete media
562 supplemented with 10 mM HEPES. Stable cell lines were selected using puromycin, and
563 293Ts expressing HA-tagged APOBEC3F or APOBEC3G were single-cell cloned prior to
564 flow cytometric screening.

565 **Antibody-Free Magnetic Cell Sorting (AFMACS)**

AFMACS-based selection of CEM-T4s using the streptavidin-binding SBP-ΔLNGFR affinity tag was carried out essentially as previously described (Matheson et al., 2014; Naamati et al., 2019). Briefly, 1×10^6 CEM-T4s/condition were infected with VSV-g pseudotyped HIV-AFMACS viruses at an MOI of 0.5. 48 hr post-infection, washed cells were resuspended in incubation buffer (IB; Hank's balanced salt solution, 2% dialysed FCS, 1x RPMI Amino Acids Solution (Sigma), 2 mM L-glutamine, 2 mM EDTA and 10 mM HEPES) at 10^7 cells/ml and incubated with Dynabeads Biotin Binder (Invitrogen) at a bead-to-total cell ratio of 4:1 for 30 min at 4 °C. Bead-bound cells expressing SBP-ΔLNGFR were selected using a DynaMag-2 magnet (Invitrogen), washed to remove uninfected cells, then released from the beads by incubation in complete RPMI with 2 mM biotin for 15 min at room temperature (RT). Enrichment was assessed by flow cytometry pre- and post-selection.

Proteomics

Sample preparation

For TMT-based whole cell proteomic analysis of transduced or infected CEM-T4s, washed cell pellets were lysed in 50 mM HEPES pH 8 with 5% SDS followed by 10 min (30 sec on/off) sonication in a Bioruptor Pico sonicator (Diagenode) at 18 °C. Lysates were quantified by BCA assay (Thermo Scientific) and 25 µg (transduced CEM-T4s, experiments 1-2) or 10 µg (infected and AFMACS-selected CEM-T4s, experiment 3) total protein/condition used for further analysis.

Sample volumes were equalised with lysis buffer and proteins reduced and alkylated by addition of 10mM TCEP and 20mM iodoacetamide followed by incubation at RT for 30 min, protected from light. Samples were then processed using S-Trap micro columns (Protifi). To each sample 10% v/v H_3PO_4 was added and samples mixed by vortexing briefly. 6 volumes of 90% MeOH HEPES pH 7.1 (loading buffer) were then added and pipette-mixed before loading onto columns using a vacuum manifold.

591 Samples were then washed with 4x 150 µl loading buffer. A 1:25 enzyme:protein ratio of
592 LysC/trypsin mix (Promega) was added to each column in 30 µl of 50 mM HEPES pH 8 with
593 0.1% sodium deoxycholate (SDC). Columns were placed into microcentrifuge tubes and
594 incubated for 6 hr at 37 °C in a Thermomixer S (Eppendorf) without shaking. Open tubes of
595 water were placed in empty positions and the Thermomixer lid used to minimise evaporation.

596 After incubation, peptides were eluted in three stages: 40 µl 10 mM HEPES pH 8; 35 µl 0.2%
597 formic acid (FA); then 35 µl 0.2% FA in 50% Acetonitrile (ACN). Samples were dried for a
598 short period in a vacuum centrifuge to evaporate ACN and then acidified with FA to
599 precipitate SDC. Samples were then made up to ~100 µl with water, then 600 µl ethyl
600 acetate was added and samples vortexed vigorously. After centrifugation at 15,000 g for 5
601 min the lower phase (containing peptides) was retained and the upper phase (containing
602 SDC and ethyl acetate) was discarded.

603 After drying fully in a vacuum centrifuge, samples were resuspended in 21 µl 100 mM
604 HEPES pH 8, to which was added 0.2 mg of TMT label dissolved in 9 µl ACN. After 1 hr
605 incubation at RT samples were analysed by LCMS to ensure complete labelling, then pooled
606 and dried by ~50% in a vacuum centrifuge. The pooled sample was made up to ~1ml in a
607 final concentration of 0.1% trifluoroacetic acid (TFA) and the pH was adjusted to <2 with FA.
608 The samples were then subjected to C18 SPE clean-up using 500 mg Sep-Pak tC18
609 cartridges (Waters). Columns was wetted with 1 ml ACN and equilibrated with 3 ml 0.1%
610 TFA before loading the sample, washing with 2 ml 0.1% TFA and eluting with 250 µl 40%
611 ACN, 250 µl 80% ACN and 250 µl 80% ACN. The eluates were dried in a vacuum
612 centrifuge.

613 Off-line high pH reversed-phase (HpRP) peptide fractionation

614 HpRP fractionation was conducted on an Ultimate 3000 UHPLC system (Thermo Scientific)
615 equipped with a 2.1 mm × 15 cm, 1.7 µm Kinetex EVO C18 column (Phenomenex). Solvent

616 A was 3% ACN, Solvent B was 100% ACN, and solvent C was 200 mM ammonium formate
617 (pH 10). Throughout the analysis solvent C was kept at a constant 10%. The flow rate was
618 400 μ l/min and UV was monitored at 280 nm. Samples were loaded in 90% A for 10 min
619 before a gradient elution of 0–10% B over 10 min (curve 3), 10-34% B over 21 min (curve 5),
620 34-50% B over 5 min (curve 5) followed by a 10 min wash with 90% B. 15 sec (100 μ l)
621 fractions were collected throughout the run. Peptide-containing fractions were orthogonally
622 recombined into 24 (transduced CEM-T4s, experiments 1-2) or 12 (infected and AFMACS-
623 selected CEM-T4s, experiment 3) fractions, dried in a vacuum centrifuge and stored at -20
624 °C prior to analysis.

625 Mass spectrometry

626 Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to
627 an Ultimate 3000 RSLC nano UHPLC (Thermo Scientific). Solvent A was 0.1% FA and
628 solvent B was ACN/0.1% FA. HpRP fractions were resuspended in 20 μ l 5% DMSO 0.5%
629 TFA and 10 μ l injected. Fractions were loaded at 10 μ l/min for 5 min on to an Acclaim
630 PepMap C18 cartridge trap column (300 μ m $\times$ 5 mm, 5 μ m particle size) in 0.1% TFA. After
631 loading, a linear gradient of 3–32% B over 3 hr was used for sample separation over a
632 column of the same stationary phase (75 μ m $\times$ 50 cm, 2 μ m particle size) before washing
633 with 90% B and re-equilibration. An SPS/MS3 acquisition was used for all samples and was
634 run as follows. MS1: quadrupole isolation, 120,000 resolution, 5×10^5 AGC target, 50 msec
635 maximum injection time, ions injected for all parallelisable time. MS2: quadrupole isolation at
636 an isolation width of m/z 0.7, CID fragmentation (NCE 35) with the ion trap scanning out in
637 rapid mode from m/z 120, 8×10^3 AGC target, 70 msec maximum injection time, ions
638 accumulated for all parallelisable time. In synchronous precursor selection mode the top 10
639 MS2 ions were selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at
640 50,000 resolution with an AGC target of 2×10^4 and a maximum accumulation time of 120
641 msec, ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had

642 a target time of 3 sec. Dynamic exclusion was set to ± 10 ppm for 90 sec, MS2
643 fragmentation was triggered at 5×10^3 ions.

644 Data processing

645 Spectra were searched using Mascot within Proteome Discoverer 2.2 in two rounds. The first
646 search was against the UniProt human reference proteome, a custom HIV proteome
647 (adjusted to include the exact protein coding sequences used) and a compendium of
648 common contaminants (Global Proteome Machine). The second search took all unmatched
649 spectra from the first search and searched against the human trEMBL database. The
650 following search parameters were used. MS1 tol: 10 ppm; MS2 tol: 0.6 Da; fixed mods:
651 carbamidomethyl (C) and TMT (N-term, K); var mods: oxidation (M); enzyme: trypsin (/P).
652 MS3 spectra were used for reporter ion based quantitation with a most confident centroid
653 tolerance of 20 ppm. PSM FDR was calculated using Mascot percolator and was controlled
654 at 0.01% for 'high' confidence PSMs and 0.05% for 'medium' confidence PSMs.
655 Normalisation was automated and based on total s/n in each channel.
656 All proteomics datasets described in this study will be deposited to the ProteomeXchange
657 consortium (accessible at: <http://proteomecentral.proteomexchange.org>) prior to publication
658 and are summarised in **Figure 2–source data file 1**, **Figure 6–source data file 1** and
659 **Figure 7–source data file 1**.

660 Statistical analysis

661 Abundances of proteins/peptides satisfying at least a 'medium' FDR confidence were
662 subjected to further analysis in Excel 2016 (Microsoft) and R v.3.6.1 (R Core Team, 2019).

663 For proteomic experiments 1 and 2, abundances in the 3 mock-transduced samples were
664 used to calculate sample means ($\bar{x}$) and standard deviations (S) for each protein.
665 Corresponding protein abundances in transduced cells were then compared with these
666 values to determine standard scores (t -scores) for each condition: $(X - \bar{x})/S$ (where X

represents protein abundance in the condition of interest). Significant outliers were identified by calculating two-tailed p -values using a t -distribution with 2 degrees of freedom. Illustrative t -score/ p -value calculations for PPP2R5A in cells transduced with WT Vif or a control lentivector are shown in **Figure 2–figure supplement 2**.

For proteomic experiment 3, mean protein abundances in cells infected with Δ Vpr-Vif WT, Δ Vpr- Δ Vif, or Δ Vpr-Vif AYR viruses were compared with mean protein abundances in mock-infected cells. For each pair-wise comparison, a moderated t -test was conducted using the limma R package (Ritchie et al., 2015; Schwammle et al., 2013). Benjamini-Hochberg FDR-adjusted p values (q values) were used to control the false discovery rate.

Antibodies

Antibodies for immunoblot and flow cytometry are detailed in the **Key resources table**. Anti-HIV-1 Vif (Simon et al., 1995) was obtained from the AIDS Reagent Program, Division of AIDS, NIAID, NIH (Dr M. H. Malim).

Flow cytometry

Antibody staining

For the flow cytometric screen in 293Ts, a sub-confluent 24-well/condition was harvested with trypsin-EDTA, fixed and permeabilised using the Cytotfix/Cytoperm Fixation and Permeabilisation Kit (BD Biosciences) according to the manufacturer's instructions. Permeabilised cells were stained with AF647-conjugated rabbit anti-HA antibody (abcam) for 20 min at RT, washed, and analysed with an LSR Fortessa flow cytometer (BD Biosciences). Doublets were excluded by comparing SSC-W with SSC-H. Depletion of HA-tagged PPP2R5B, APOBEC3F, or APOBEC3G was quantified by the ratio of median AF647 fluorescence in GFP+ (transfected, Vif+)/GFP- (untransfected, Vif-) cells for each condition, after deducting background fluorescence of control 293Ts (no HA-tagged protein expression).

692 For titration of HIV-AFMACS viruses, typically 2×10^5 washed CEM-T4s were stained with
693 fluorochrome-conjugated anti-LNGFR and anti-CD4 for 15 min at 4 °C then fixed in PBS/1%
694 paraformaldehyde and analysed as above. For titration of lentivectors, GFP fluorescence
695 was quantified without antibody staining.

696 DNA content

697 For cell cycle analysis in transduced CEM-T4s and transduced/transfected HeLas, 1×10^6
698 cells/condition (CEM-T4s) or a 50% confluent 6-well/condition (HeLas) were washed with
699 PBS, then fixed for 30 min with ice-cold 90% methanol. Fixed cells were stained with 7-AAD
700 at 25 µg/ml for 30 mins at 37 °C, then analysed with an LSR Fortessa flow cytometer (BD
701 Biosciences). Doublets were excluded by comparing SSC-W with SSC-H. The FlowJo cell
702 cycle platform was used to determine the fraction of cells in each phase of cell cycle. G2/M
703 cell cycle arrest was quantified by the ratio of cells in G2/M for each condition, compared
704 with mock-transduced/transfected cells.

705 For cell cycle analysis in CEM-T4s infected with HIV-AFMACS, cells were first stained with
706 FITC-conjugated anti-LNGFR (BioLegend), then washed, fixed and stained with 7-AAD and
707 analysed as above. G2/M cell cycle arrest was quantified by the ratio of cells in G2/M for
708 LNGFR+ (infected, HIV+)/LNGFR- (uninfected) cells for each condition.

709 For cell cycle analysis in primary human CD4+ T cells infected with HIV-AFMACS,
710 CD3/CD28 Dynabeads were first removed using a DynaMag-2 magnet (Invitrogen). Cells
711 were stained with FITC-conjugated anti-LNGFR (BioLegend) and BV421-conjugated anti
712 CD4 (BioLegend), then washed, fixed, stained with 7-AAD and analysed as above. G2/M cell
713 cycle arrest was quantified by the ratio of cells in G2/M for LNGFR+ CD4- (infected,
714 HIV+)/LNGFR- CD4+ (uninfected) cells for each condition.

715 **Immunoblotting**

716 Washed cell pellets were lysed in PBS/2% SDS supplemented with Halt Protease and
717 Phosphatase Inhibitor Cocktail (Thermo Scientific) and benzonase (Sigma) for 10 min at RT.

Post-nuclear supernatants were heated in Laemmli Loading Buffer for 5 min at 95 °C, separated by SDS-PAGE and transferred to Immobilon-P membrane (Millipore). Membranes were blocked in PBS/5% non-fat dried milk (Marvel)/0.2% Tween and probed with the indicated primary antibody overnight at 4 °C. Reactive bands were visualised using HRP-conjugated secondary antibodies and SuperSignal West Pico or Dura chemiluminescent substrates (Thermo Scientific). Typically 10–20 µg total protein was loaded per lane.

Quantitative reverse transcription PCR

For quantification of PPP2R5 subunit mRNA levels, total RNA was extracted using TRIzol reagent (Invitrogen), followed by DNase I treatment. cDNA was synthesised using the Superscript III First-Strand Synthesis System (Invitrogen) with Oligo(dT) (Invitrogen), and 10 ng/test subjected to real-time PCR using the primers tabulated in **Supplementary file 1** (PCR primers for real-time PCR) and the SYBR Green PCR Master Mix (Thermo Scientific).

To control for PCR efficiency and allow comparison of abundances between different PPP2R5 subunits, standard curves were generated using plasmids encoding PPP2R5A, PPP2R5B, PPP2R5C, PPP2R5D and PPP2R5E (all Addgene), together with housekeeping gene Tata Binding Protein (TBP, Source Bioscience). Abundances of different PPP2R5 subunits for each cell type or condition were derived from the corresponding standard curves, and expressed as mRNA copy numbers relative to TBP as an endogenous reference.

Visualization of Vif-CUL5 crystal structure

The previously determined structure of Vif in complex with CUL5, CBF β , and ELOB/C (PDB ID: 4N9F) was used to identify solvent-exposed residues to be mutated in this study (Guo et al., 2014). Structural analysis and figures were generated using PyMOL Molecular Graphics System, Version 2.0 (Schrödinger).

Bioinformatic analysis of Vif polymorphisms

743 Protein sequence Web Alignments for Vif, Env, Gag and Nef were downloaded from the Los
744 Alamos HIV Sequence Alignments Database (accessible at: <http://www.hiv.lanl.gov/>). The
745 following server options were selected: Alignment type, Web (all complete sequences);
746 Organism, HIV-1/SIVcpz; Subtype, M group without recombinants (A-K); DNA/Protein,
747 protein; Year, 2018; Format, FASTA.

748 These alignments contain all non-recombinant HIV-1 M group sequences from the Los
749 Alamos HIV Sequence Database, with the following exceptions: only one sequence per
750 patient is included; a single representative is included of very similar sequences; and
751 sequences unlikely to represent naturally-occurring, viable viruses are excluded. We further
752 subdivided the sequences according to viral clade (subtype) using the information in the
753 sequence name e.g. B.FR.83.HXB2 is assigned to clade B. Analyses were conducted for
754 both clade B viruses and all non-recombinant HIV-1 M group viruses.

755 To examine amino acid polymorphism in naturally occurring Vif variants at positions
756 corresponding to residues 31, 33/34 and 128 of NL4-3 Vif, sequence logos were generated
757 using WebLogo (Crooks et al., 2004). Further data analysis was conducted in R v.3.6.1 (R
758 Core Team, 2019). In brief, residues at each position of interest were extracted using the
759 seqinr R package (Charif and Lobry, 2007), then frequencies were calculated and graphical
760 summaries generated using the ggplot R package (Wickham, 2009). To identify covariance
761 (non-random association) between polymorphisms at positions 31 and 128, 2x2 contingency
762 tables comparing frequencies of key residue pairs were constructed, then subjected to two-
763 tailed Fisher's exact tests of independence (Wang and Lee, 2007).

764 To construct phylogenetic trees, only viruses with protein sequences available for all of Vif,
765 Env, Gag and Nef were included. This enabled direct comparison of trees based on different
766 viral proteins. Multiple sequence alignments and phylogenetic tree data (in Newick format)
767 for each viral protein were generated using the Clustal Omega web server (Sievers and
768 Higgins, 2014), then visualised using the ggtree R package (Yu et al., 2018).

769 All alignment and sequence files, scripts and details of the bioinformatic analyses described
770 here are available at: https://github.com/annaprotasio/Marelli_et_al_HIV_Vif.

771 **General statistical analysis**

772 Where indicated, Student's *t*-tests (unpaired two-sample, assuming homoscedasticity, two-
773 tailed), Fisher's exact tests (two-tailed) and 95% confidence intervals were calculated using
774 Prism 7.0 (GraphPad). General data manipulation was conducted using Excel 2016
775 (Microsoft).

Acknowledgements

This work was supported by the MRC (CSF MR/P008801/1 to NJM), NHSBT (WPA15-02 to NJM), the Wellcome Trust (PRF 210688/Z/18/Z to P.J.L), the NIHR Cambridge BRC, and a Wellcome Trust Strategic Award to CIMR. The authors thank Dr Reiner Schulte and the CIMR Flow Cytometry Core Facility team, and members of the Matheson and Lehner laboratories for critical discussion.

Competing interests

The authors declare no competing interests.

Figures

Figure 1. Flow cytometric screen of HIV-1 Vif point mutants

(A) Depletion of endogenous PPP2R5D by HIV-1 Vif. CEM-T4s were transduced with lentiviruses encoding either EGFP-SBP- Δ LNGFR (Ctrl) or EGFP-P2A-Vif (Vif) at an MOI of 3, then lysed in 2% SDS and analysed by immunoblot with anti-Vif, anti-PPP2R5D and anti- β -actin (loading control) antibodies after 48 hr. Green arrows, Ctrl vs Vif.

(B) Solvent-accessible surfaces of Vif (pale blue) in complex with CUL5 (dark grey), ELOB/C (grey) and CBF- β (light grey). Residues highlighted in yellow were targeted in our library of point mutants (total 34). Residues highlighted in red specifically affected the depletion of PPP2R5B, but not APOBEC3G.

(C-D) Depletion of PPP2R5B (C) or APOBEC3G (D) by selected Vif point mutants. 293Ts stably expressing HA-tagged PPP2R5B or APOBEC3G were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr (see **Figure 1-figure supplement 1B-C**). For each Vif point mutant, abundance of PPP2R5B or APOBEC3G is shown as a ratio of AF647 fluorescence in GFP+ (transfected, Vif+) to GFP- (untransfected, Vif-) cells, after deducting background fluorescence of control 293Ts (no HA-tagged protein expression). Individual data points represent biological replicates (minimum 3). Mean values with standard error of the mean (SEM) are indicated. Vif point mutants specifically affecting the depletion of PPP2R5B are highlighted in red. Ctrl, control constructs encoding EGFP or EGFP-SBP- Δ LNGFR. Data for other Vif point mutants are shown in **Figure 1-figure supplement 2A-B**. Green arrows, Ctrl vs Vif WT.

(E) Representative data from (C-D). Green, GFP+, transfected cells (Vif+); grey, GFP-, untransfected cells (Vif-); dotted line, background staining of control 293Ts (no HA-tagged protein expression).

810

811 **Figure 2. Depletion of endogenous APOBEC3 and PPP2R5 family proteins by HIV-1 Vif**
812 **point mutants**

813 (A) Depletion of endogenous PPP2R5D by selected Vif point mutants. CEM-T4s were
814 transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then lysed in 2% SDS
815 and analysed by immunoblot with anti-Vif, anti-PPP2R5D and anti- β -actin (loading control)
816 antibodies after 48 hr. Ctrl, control construct encoding EGFP-SBP- Δ LNGFR.

817 (B) Overview of proteomic experiment 1 (selected Vif point mutants). CEM-T4s were
818 transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then analysed by TMT-
819 based quantitative proteomics after 48 hr. Mock_1/2/3, biological replicates. Ctrl, control
820 construct encoding EGFP-SBP- Δ LNGFR.

821 (C-D) Depletion of endogenous PPP2R5 family (C) or APOBEC3 family (D) proteins by
822 selected Vif point mutants in cells from (B). For each Vif point mutant, abundance of
823 respective PPP2R5 or APOBEC family members is shown as a ratio to the mean abundance
824 of the same family member in the 3 mock-transduced samples. Significant outliers from the
825 distribution of abundances in mock-transduced samples are highlighted (see **Materials and**
826 **methods** and **Figure 2-figure supplement 2** for further details). * $p < 0.05$.

827

828 **Figure 3. Regulation of cell cycle by HIV-1 Vif point mutants**

829 (A) Phosphorylation of aurora kinases in the presence of selected Vif point mutants. CEM-
830 T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then lysed in
831 2% SDS and analysed by immunoblot with anti-Vif, anti-phospho-AURK, anti-total AURKB
832 and anti-p97 (loading control) antibodies after 48 hr. Ctrl, control construct encoding EGFP-
833 SBP- Δ LNGFR.

(B) Regulation of cyclin B1 by selected Vif point mutants in cells from proteomic experiment 1 (**Figure 2B**). For each Vif point mutant, abundance of cyclin B1 is shown as a ratio to the mean abundance in the 3 mock-transduced samples. Significant outliers from the distribution of abundances in mock-transduced samples are highlighted (see **Materials and methods** for details). * $p < 0.05$; ** $p < 0.05$.

(C-D) Regulation of cell cycle by selected Vif point mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data (C) from 3 biological replicates (D) are shown. For each Vif point mutant, the fraction of cells in G2/M is shown as a ratio to the fraction of cells in G2/M in mock-transduced cells. Individual data points reflect biological replicates. Mean values with SEM are indicated. Significant differences compared with mock-transduced cells are highlighted (*t*-tests). * $p < 0.05$. Ctrl, control construct encoding EGFP-SBP- Δ LNFR.

Figure 4. Regulation of cell cycle by depletion of PPP2R5 family subunits

(A-B) Regulation of cell cycle by individual vs pooled PPP2R5A-E siRNA. HeLas were transfected with the indicated siRNA, then fixed in 90% MeOH methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data (A) from 3 biological replicates (B) for each of 2 panels of siRNA are shown. For each condition, the fraction of cells in G2/M is shown as a ratio to the fraction of cells in G2/M in mock-transfected cells. Individual data points reflect biological replicates. Mean values with SEM are indicated. Significant differences compared with mock-transduced cells are highlighted (*t*-tests). * $p < 0.05$. *** $p < 0.0005$. Ctrl siRNA, MISSION siRNA Universal Negative Control #1. Blue histograms/data points, siRNA panel 1. Red histograms/data points, siRNA panel 2.

(C-D) Regulation of cell cycle by combinations of pooled PPP2R5A-E siRNA. HeLas were transfected with the indicated siRNA, then fixed in 90% MeOH methanol, stained with 7-AAD

860 and analysed by flow cytometry after 48 hr. Representative data (C) from 3 biological
861 replicates (D) for each of 2 panels of siRNA are shown. All details as per (A-B).

862

863 **Figure 5. Analysis of naturally occurring HIV-1 Vif variants**

864 (A) Amino acid polymorphism amongst 2,171 naturally occurring HIV-1 M group Vif variants
865 (clade B). Sequence logos (left panel) and bar chart (right panel) highlight frequencies of
866 amino acids corresponding to residues 31, 33 and 128 of NL4-3 Vif. In the sequence logos,
867 polar amino acids (AAs) are depicted in green; neutral AAs, in purple; basic AAs, in blue;
868 acidic AAs, in red; and hydrophobic AAs, in black. An equivalent bar chart for all naturally
869 occurring non-recombinant HIV-1 M group Vif variants (all clades) is shown in **Figure 5–**
870 **figure supplement 1**.

871 (B) Depletion of PPP2R5B by selected Vif point mutants. 293Ts stably expressing HA-
872 tagged PPP2R5B were transfected with constructs encoding EGFP-P2A-Vif, then
873 fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow
874 cytometry after 36 hr. Ctrl, control construct encoding EGFP-SBP- Δ LNGFR. All details as
875 per **Figure 1C**.

876 (C) Sequence alignments of selected Vif variants. Amino acids corresponding to residues
877 31, 33 and 128 of NL4-3 Vif are highlighted in red (red boxes). Other residues targeted in our
878 library of point mutants and known to interact with APOBEC3G (green), APOBEC3C/F
879 (orange) and APOBEC3H (blue) are also shown (as per **Figure 1–figure supplement 2C**).
880 Additional annotations (α -helices, β -sheets, Zn finger and BC-box) are based on the
881 published Vif-CUL5 crystal structure (Guo et al., 2014).

882 (D) Depletion of PPP2R5B by selected Vif variants. 293Ts stably expressing HA-tagged
883 PPP2R5B were transfected with constructs encoding EGFP-P2A-Vif, then
884 fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow

cytometry after 36 hr. Ctrl, control construct encoding EGFP-SBP-ΔLNGFR. All details as per (B) and **Figure 1C**.

Figure 6. Depletion of endogenous APOBEC3 and PPP2R5 family proteins by naturally occurring HIV-1 Vif variants

(A) Overview of proteomic experiment 2 (naturally occurring Vif variants and corresponding point mutants). CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then analysed by TMT-based quantitative proteomics after 48 hr. Mock_1/2/3, biological replicates. Ctrl, control construct encoding EGFP. NL4-3 AYR, NL4-3 Vif with both I31A and RI127/128YR mutations.

(B-C) Depletion of endogenous PPP2R5 family (B) or APOBEC3 family (C) proteins by naturally occurring Vif variants and corresponding point mutants in cells from (A). For each Vif variant or point mutant, abundance of respective PPP2R5 or APOBEC family members is shown as a ratio to the mean abundance of the same family member in the 3 mock-transduced samples. Significant outliers from the distribution of abundances in mock-transduced samples are highlighted (see **Materials and methods** and **Figure 2–figure supplement 2** for further details). *p<0.05; **p<0.005. † Not detected in this experiment (PPP2R5B, APOBEC3F).

(D) Regulation of cell cycle by naturally occurring Vif variants and corresponding point mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Individual data points reflect 3 biological replicates (representative data, **Figure 6–figure supplement 2**). **p<0.005. ***p<0.0005. Ctrl, control construct encoding EGFP. NL4-3 AYR, NL4-3 Vif with both I31A and RI127/128YR mutations. All other details as per **Figure 3C-D**.

Figure 7. Selective regulation of PPP2R5 family subunits during HIV-1 infection

(A) Overview of proteomic experiment 3 (viral infections). CEM-T4s were infected with HIV-AFMACS viruses at an MOI of 0.5, then purified using AFMACS (**Figure 7-figure supplement 1A-B**) and analysed by TMT-based quantitative proteomics after 48 hr. Biological replicates are shown. Vif AYR, NL4-3 Vif with both I31A and RI127/128YR mutations.

(B) Protein abundances in HIV-infected vs mock-infected cells from (A). Volcano plots show statistical significance (y-axis) vs fold change (x-axis) for 6,294 viral and cellular proteins (no missing values). Pair-wise comparisons of mock-infected cells with cells infected with Δ Vpr-Vif WT (left panel), Δ Vpr- Δ Vif (middle panel) or Δ Vpr-Vif AYR (right panel) viruses are shown. Proteins with Benjamini-Hochberg FDR-adjusted p values (q values) <0.05 (black crosses) or >0.05 (grey crosses) are indicated (FDR threshold of 5%). Proteins highlighted in each plot are summarised in the key. 4 out of 5 PPP2R5 family subunits (A/C/D/E) were quantitated, but only 1 out of 7 APOBEC3 family member (C).

(C) Regulation of cell cycle in HIV-infected CEM-T4s. Cells were infected with HIV-AFMACS viruses at an MOI of 0.5, then stained with FITC-conjugated anti-LNGFR antibody, fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data (upper panels) from 3 biological replicates (lower panel) are shown. Green, LNGFR+ cells (HIV+); grey, LNGFR- cells (uninfected). For each virus, the fraction of HIV+ (LNGFR+) cells in G2/M is shown as a ratio to the fraction of uninfected (LNGFR-) cells in G2/M. Individual data points reflect biological replicates. Mean values with SEM are indicated. Significant differences are highlighted for each pair-wise comparison (*t*-tests). ** $p < 0.005$.

(D) Pair-wise combinations of key amino acid polymorphisms amongst 2,171 naturally occurring HIV-1 M group Vif variants (clade B). Frequencies of amino acids corresponding to residues 31 and 128 of NL4-3 Vif are shown. An equivalent pie chart for all naturally

936 occurring non-recombinant HIV-1 M group Vif variants (all clades) is shown in **Figure 7–**
937 **figure supplement 3B.**

938 (E) Phylogenetic tree of 795 HIV-1 M group viruses (clade B) with protein sequences
939 available for all of Vif, Gag, Env and Nef (based on relatedness of Vif). Viruses encoding Vif
940 variants with I31/I128 (most active, red) and V31/R128 (least active, blue) are highlighted.
941 Equivalent phylogenetic trees based on relatedness of Gag, Env or Nef are shown in **Figure**
942 **7–figure supplement 4A.**

Figure supplements

Figure 1—figure supplement 1. Further details for site-directed mutagenesis and flow cytometric screen

(A) Overview of PCR and Gibson assembly-based approach to site-directed mutagenesis. PCR products are digested with DpnI (1 hr, 37 °C) to degrade template. Vector is digested with XhoI and KpnI, gel purified, then assembled with PCR products using the NEBuilder HiFi DNA Assembly Master Mix (1 hr, 50 °C) and transformed into competent cells. Mut_Fwd and Mut_Rvs, mutation-specific primers; Vif_Fwd and Vif_Rvs, common primers; seq, sequencing primer; red circle, site of intended mutation; red cross, intended mutation; red parallel lines, cut sites; orange boxes, overlapping sequences.

(B) Overview of flow cytometric screen. 293Ts stably expressing HA-tagged PPP2R5B or APOBEC3G were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr.

(C) Illustrative data and gating strategy for flow cytometric screen. AF647 fluorescence indicates abundance of PPP2R5B. For each Vif point mutant, AF647 fluorescence is compared between Green, GFP+, transfected cells (Vif+); grey, GFP-, untransfected cells (Vif-); dotted line, background staining of control 293Ts (no HA-tagged protein expression). Upper panels, control construct encoding EGFP; lower panels, construct encoding EGFP-P2A-Vif (WT).

Figure 1—figure supplement 2. Complete results of flow cytometric screen

(A-B) Depletion of PPP2R5B (A) or APOBEC3G (B) by all Vif point mutants targeted in our library. 293Ts stably expressing HA-tagged PPP2R5B or APOBEC3G were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr (see **Figure 1—**

figure supplement 1B-C). For each Vif point mutant, abundance of PPP2R5B or APOBEC3G is shown as a ratio of A4647 fluorescence in GFP+ (transfected, Vif+) to GFP- (untransfected, Vif-) cells. Individual data points represent biological replicates (minimum 2). Mean values with SEM are indicated. Vif point mutants specifically affecting the depletion of PPP2R5B are highlighted in red (also shown in **Figure 1B-D**). Other residues included in our screen and known to interact with APOBEC3G (green), APOBEC3C/F (orange) and APOBEC3H (blue) are also indicated (Gaddis et al., 2003; Letko et al., 2015; Nakashima et al., 2016; Ooms et al., 2016). Ctrl, control construct encoding EGFP or EGFP-SBP- Δ LNGFR.

(C) Solvent-accessible surfaces of Vif (pale blue) in complex with CUL5 (dark grey), ELOB/C (grey) and CBF- β (light grey). Residues specifically affecting the depletion of PPP2R5B are highlighted in red, together with residues included in our screen and known to interact with APOBEC3G (green), APOBEC3C/F (orange) and APOBEC3H (blue), as per (A-B).

Figure 1—figure supplement 3. Stability of selected Vif point mutants in 293Ts

293Ts were transfected with constructs encoding EGFP-P2A-Vif, then lysed in 2% SDS and analysed by immunoblot with anti-Vif, anti-GFP (transfection control) and anti- β -actin (loading control) antibodies after 48 hr. Ctrl, control construct encoding EGFP. Note that EGFP expressed from constructs encoding EGFP-P2A-Vif migrates more slowly because it retains the majority of the P2A peptide as a C-terminal tag.

Figure 1—figure supplement 4. Depletion of APOBEC3F by selected Vif point mutants

(A) 293Ts stably expressing HA-tagged APOBEC3F were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr. For each Vif point mutant, abundance

of APOBEC3F is shown as a ratio of A4647 fluorescence in GFP+ (transfected, Vif+) to GFP- (untransfected, Vif-) cells. Individual data points represent 3 biological replicates. Ctrl, control construct encoding EGFP. All details and Vif point mutants as per **Figure 1C-D**.

(B-C) Representative data from (A). All details and Vif point mutants as per **Figure 1E**, with a Vif variant encoding R15A (known to be defective for depletion of APOBEC3F) included as an additional control (B).

Figure 2–figure supplement 1. Stability of selected Vif point mutants in CEM-T4s

Expression of selected Vif point mutants in cells from proteomic experiment 1 (**Figure 2B**). For each Vif point mutant, abundance is shown as a ratio to Vif WT.

Figure 2–figure supplement 2. Calculation of *t*-scores and *p*-values

Illustrative *t*-score/*p*-value calculations for PPP2R5A in cells transduced with EGFP-SBP- Δ LNFR (control lentivector) or WT Vif. Graphs show protein abundance (x axis) vs probability density (y axis). A *t*-distribution (2 degrees of freedom) based on PPP2R5A abundances in mock-transduced cells (3 biological replicates) is shown (grey bell curve). Abundances from mock-transduced cells (grey data points, all panels), cells transduced with EGFP-SBP- Δ LNFR (Ctrl, blue data point, middle panel) or Vif WT (red data point, right panel) are projected on to the distribution for illustrative purposes. Standard scores (*t*-scores) indicate distance (number of standard deviations, *S*) from the sample mean ($\bar{x}$). Corresponding two-tailed *p*-values are shown. Note that for a *t*-distribution with 2 degrees of freedom, the 95% confidence interval lies within +/- 4.30 standard deviations of the mean, compared with +/- 1.96 standard deviations of the mean for the normal distribution (*z*-distribution).

Figure 3—figure supplement 1. Additional controls for cell cycle analysis (Vif point mutants)

(A-B) Regulation of cell cycle by selected Vif point mutants. CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data (A) from 2 biological replicates (B) are shown. Mean values are indicated. Ctrl, control construct encoding EGFP-SBP-ΔLINGFR. All other details as per **Figure 3C-D**.

Figure 3—figure supplement 2. Depletion of endogenous DPH7 and FMR1 by selected Vif point mutants

(A) Depletion of DPH7 (left panel) and FMR1 (right panel) by selected Vif point mutants in cells from proteomic experiment 1 (**Figure 2B**). For each Vif point mutant, abundances of DPH7 and FMR1 are shown as a ratio to the mean abundances in the 3 mock-transduced samples. Significant outliers from the distribution of abundances in mock-transduced samples are highlighted (see **Materials and methods** for details). * $p < 0.05$.

Figure 4—figure supplement 1. Additional controls for cell cycle analysis (okadaic acid and Vif)

(A) Regulation of cell cycle by PP2A inhibition. CEM-T4s were treated with either 100nM okadaic acid or DMSO (vehicle) for 16 hr, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry.

(B) Regulation of cell cycle in HeLas by Vif. Cells were transduced with GFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Ctrl, control construct encoding EGFP.

Figure 4—figure supplement 2. Additional controls for cell cycle analysis (PPP2R5A-E siRNA)

(A) Abundances of PPP2R5A-E transcripts in HeLas and CEM-T4s. Total RNA was analysed by quantitative reverse transcription PCR (qRT-PCR), and mRNA copy numbers expressed relative to Tata Binding Protein (TBP). Mean values with SEM are shown from 3 biological replicates.

(B) Efficiency of PPP2R5A-E knockdown. HeLas were transfected with pooled PPP2R5A-E siRNAs (as per **Figure 4**), then total RNA analysed by qRT-PCR after 24 hr. For each PPP2R5 family subunit, relative mRNA abundance is shown as a ratio to the abundance in control siRNA-transfected cells (Ctrl). Individual data points represent 3 biological replicates for each of 2 panels of siRNA. Mean values with SEM are indicated. * Relative abundance of PPP2R5B could not be quantitated because mRNA copy numbers in cells transfected with siRNA were below the linear range of the assay (cycle threshold >35).

(C) Abundances of PPP2R5A-E transcripts in HeLas stably expressing exogenous PPP2R5B. Details as per (A).

(D-E) Rescue of cell cycle progression by PPP2R5B. HeLas or HeLas stably expressing exogenous PPP2R5B were transfected with Ctrl siRNA or pooled siRNA targeting PPP2R5A, C, D and E (no B), then fixed in 90% MeOH methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data (D) from 3 biological replicates (E) for each of 2 panels of siRNA are shown. All details as per **Figure 4A-D**.

Figure 4—figure supplement 3. Additional controls for cell cycle analysis (DPH7 and FMR1 siRNA)

(A-B) Regulation of cell cycle by DPH7 and FMR1 siRNA. HeLas were transfected with the indicated siRNA, then fixed in 90% MeOH methanol, stained with 7-AAD and analysed by

flow cytometry after 48 hr. Representative data (A) from 3 biological replicates (B) for each of 2 siRNAs are shown. For each condition, the fraction of cells in G2/M is shown as a ratio to the fraction of cells in G2/M in mock-transfected cells. Individual data points reflect biological replicates. Mean values with 95% confidence intervals (CIs) are indicated. Ctrl siRNA, MISSION siRNA Universal Negative Control #1.

(C) Efficiency of DPH7 and FMR1 knockdown. Cells from (A-B) were lysed in 2% SDS 24 hr after siRNA transfection and analysed by immunoblot with anti-FMR, anti-DPH7 and anti- β -actin (loading control) antibodies.

Figure 5—figure supplement 1.

Amino acid polymorphism amongst 3,412 naturally occurring non-recombinant HIV-1 M group Vif variants (all clades). Bar chart highlights frequencies of amino acids corresponding to residues 31, 33 and 128 of NL4-3 Vif.

Figure 5—figure supplement 2. Depletion of APOBEC3G by selected Vif variants

Depletion of APOBEC3G by selected Vif variants. 293Ts stably expressing HA-tagged APOBEC3G were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr. Ctrl, control construct encoding EGFP-SBP- Δ LNGFR. All details as per **Figure 1D**.

Figure 6—figure supplement 1. Sequence of Exonic Splicing Silencer of Vpr (ESSV) in NL4-3 and YU2 Vif variants

The ESSV (highlighted in bold) is a short nucleotide element within the HIV-1 Vif open reading frame (exon 3) required to repress splicing at HIV-1 3' splice site A2 and allow accumulation of unspliced mRNA, production of Gag and HIV viral replication (Madsen and

Stoltzfus, 2005). Inhibitory activity is dependent on three (Py/A)UAG motifs (indicated with black lines). Introduction of an isolated I128R mutation into NL4-3 Vif would disrupt the second (Py/A)UAG motif. Conversely, simultaneous introduction of an R127Y mutation (as in YU2 Vif) maintains three (Py/A)UAG motifs. Note that the nucleotide (nucl) and amino acid (aa) sequences flanking these positions is otherwise conserved between NL4-3 and YU2 viruses.

Figure 6—figure supplement 2. Regulation of cell cycle by naturally occurring Vif variants and corresponding point mutants (representative data)

CEM-T4s were transduced with lentiviruses encoding EGFP-P2A-Vif at an MOI of 3, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry after 48 hr. Representative data from **Figure 6D**.

Figure 6—figure supplement 3. Depletion of PPP2R5B, APOBEC3G and APOBEC3F by Vif AYR

(A-B) 293Ts stably expressing HA-tagged PPP2R5B, APOBEC3G or APOBEC3F were transfected with constructs encoding EGFP-P2A-Vif, then fixed/permeabilised, stained with AF647-conjugated anti-HA antibody and analysed by flow cytometry after 36 hr. Representative data (A) from 3 biological replicates (B) are shown. Ctrl, control construct encoding EGFP. All details as per **Figure 1C-D**.

Figure 7—figure supplement 1. AFMACS-based purification of infected cells for proteomic experiment 3 (viral infections)

(A-B) HIV-infected cells from **Figure 7A** were stained with anti-LNGFR and anti-CD4 antibodies and analysed by flow cytometry before (input) and after (purified vs flow-through)

selection using AFMACS. Purified cells were used for proteomic analysis. Infected cells express the SBP-ΔLNGFR cell surface affinity tag (LNGFR+) and downregulate CD4 through the action of Nef and Vpu (Guy et al., 1987; Naamati et al., 2019; Willey et al., 1992). Representative data (A) from 3 biological replicates (B) are shown. Vif AYR, NL4-3 Vif with both I31A and R1127/128YR mutations.

Figure 7—figure supplement 2. Regulation of cell cycle in HIV-infected primary human CD4+ T cells

(A-B) Primary human CD4+ T cells were activated with CD3/CD28 Dynabeads and infected with HIV-AFMACS viruses 2 days post-activation at an MOI of 0.5. After a further 48 hr, cells were stained with FITC-conjugated anti-LNGFR and BV421-conjugated anti-CD4 antibodies, then fixed in 90% methanol, stained with 7-AAD and analysed by flow cytometry. Upper and lower panels show independent experiments using cells from 2 different donors (A). Green, LNGFR+ CD4- cells (HIV+); grey, LNGFR- CD4+ cells (uninfected). For each virus, the fraction of HIV+ (LNGFR+ CD4-) cells in G2/M is shown as a ratio to the fraction of uninfected (LNGFR- CD4+) cells in G2/M. Mean values are indicated.

Figure 7—figure supplement 3. Additional bioinformatics analysis

(A) Contingency tables showing combinations of key amino acid polymorphisms amongst naturally occurring HIV-1 M group Vif variants (clade B) summarised in **Figure 7D**.

(B) Pair-wise combinations of key amino acid polymorphisms amongst 3,412 naturally occurring non-recombinant HIV-1 M group Vif variants (all clades). Frequencies of amino acids corresponding to residues 31 and 128 of NL4-3 Vif are shown. Same sequences as

Figure 5—figure supplement 1.

1144 (C) Contingency tables showing combinations of key amino acid polymorphisms amongst
1145 naturally occurring non-recombinant HIV-1 M group Vif variants (all clades) summarised in
1146 (B).

1147

1148 **Figure 7—figure supplement 4. Additional phylogenetic trees**

1149 (A) Phylogenetic trees of 795 HIV-1 M group viruses (clade B) with protein sequences
1150 available for all of Vif, Gag, Env and Nef (based on relatedness of Gag, Env or Nef). Viruses
1151 encoding Vif variants with I31/I128 (most active, red) and V31/R128 (least active, blue) are
1152 highlighted.

1153 (B) Phylogenetic trees of 1,649 naturally occurring non-recombinant HIV-1 M group viruses
1154 (all clades) with protein sequences available for all of Vif, Gag, Env and Nef (based on
1155 relatedness of Vif). In the left panel, viruses encoding Vif variants with I31/I128 (most active,
1156 red) and V31/R128 (least active, blue) are highlighted. In the right panel (same phylogenetic
1157 tree), viruses are coloured according to clade (as indicated).

Source data

Figure 2—source data 1. Complete data from proteomic experiment 1 (selected Vif point mutants)

Complete dataset (unfiltered) from TMT-based quantitative proteomic experiment illustrated in **Figure 2B**. For each protein, normalised, unscaled protein abundances, the number of unique peptides used for protein quantitation, and the protein FDR confidence are shown.

Figure 6—source data 1. Complete data from proteomic experiment 2 (naturally occurring Vif variants and corresponding point mutants)

Complete dataset (unfiltered) from TMT-based quantitative proteomic experiment illustrated in **Figure 6A**. For each protein, normalised, unscaled protein abundances, the number of unique peptides used for protein quantitation, and the protein FDR confidence are shown.

Figure 7—source data 1. Complete data from proteomic experiment 3 (viral infections)

Complete dataset (unfiltered) from TMT-based quantitative proteomic experiment illustrated in **Figure 7A**. For each protein, normalised, unscaled protein abundances, the number of unique peptides used for protein quantitation, and the protein FDR confidence are shown.

1175 **Supplementary files**

1176 **Supplementary file 1. DNA and RNA sequences**

1177 Sequences of PCR primers for Vif mutant library construction, codon-optimised Vif variants
1178 synthesised as gBlocks, Vif coding sequences in HIV-AFMACS viruses, the C-terminal
1179 4xHA-tagged APOBEC3F coding sequence in pHRSIN-S-W-pGK puro, oligonucleotides for
1180 RNAi and primers for qRT-PCR.

References

- Ajay, A.K., Upadhyay, A.K., Singh, S., Vijayakumar, M.V., Kumari, R., Pandey, V., Boppana, R., and Bhat, M.K. (2010). Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. *Mol Cancer* 9, 204.
- Bagga, S., and Bouchard, M.J. (2014). Cell cycle regulation during viral infection. *Methods Mol Biol* 1170, 165-227.
- Berger, G., Durand, S., Fargier, G., Nguyen, X.N., Cordeil, S., Bouaziz, S., Muriaux, D., Darlix, J.L., and Cimarelli, A. (2011). APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. *PLoS Pathog* 7, e1002221.
- Binka, M., Ooms, M., Steward, M., and Simon, V. (2012a). The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. *J Virol* 86, 49-59.
- Binka, M., Ooms, M., Steward, M., and Simon, V. (2012b). The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. 86, 49-59.
- Charif, D., and Lobry, J.R. (2007). Seqin{R} 1.0-2: a contributed package to the {R} project for statistical computing devoted to biological sequences retrieval and analysis. In *Structural approaches to sequence evolution: Molecules, networks, populations*, U. Bastolla, M. Porto, R.H. E., and M. Vendruscolo, eds. (New York: Springer Verlag), pp. 207-232.
- Chen, G., He, Z., Wang, T., Xu, R., and Yu, X.F. (2009). A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G. *J Virol* 83, 8674-8682.
- Compton, A.A., Malik, H.S., and Emerman, M. (2013). Host gene evolution traces the evolutionary history of ancient primate lentiviruses. *Philos Trans R Soc Lond B Biol Sci* 368, 20120496.

1206 Conticello, S.G., Harris, R.S., and Neuberger, M.S. (2003). The Vif protein of HIV triggers
1207 degradation of the human antiretroviral DNA deaminase APOBEC3G. *Curr Biol* 13, 2009-
1208 2013.

1209 Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo: a sequence
1210 logo generator. *Genome Res* 14, 1188-1190.

1211 Dang, Y., Wang, X., Zhou, T., York, I.A., and Zheng, Y.H. (2009). Identification of a Novel
1212 WxSLVK Motif in the N Terminus of Human Immunodeficiency Virus and Simian
1213 Immunodeficiency Virus Vif That Is Critical for APOBEC3G and APOBEC3F Neutralization. *J*
1214 *Virol* 83, 8544-8552.

1215 DeHart, J.L., Bosque, A., Harris, R.S., and Planelles, V. (2008). Human immunodeficiency
1216 virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase
1217 complex that targets APOBEC3 proteins for degradation. *J Virol* 82, 9265-9272.

1218 Doehle, B.P., Schafer, A., and Cullen, B.R. (2005). Human APOBEC3B is a potent inhibitor
1219 of HIV-1 infectivity and is resistant to HIV-1 Vif. *Virology* 339, 281-288.

1220 Evans, E.L., 3rd, Becker, J.T., Fricke, S.L., Patel, K., and Sherer, N.M. (2018). HIV-1 Vif's
1221 Capacity To Manipulate the Cell Cycle Is Species Specific. *J Virol* 92.

1222 Feng, Y., Baig, T.T., Love, R.P., and Chelico, L. (2014). Suppression of APOBEC3-mediated
1223 restriction of HIV-1 by Vif. *Front Microbiol* 5, 450.

1224 Fenton-May, A.E., Dibben, O., Emmerich, T., Ding, H., Pfafferott, K., Aasa-Chapman, M.M.,
1225 Pellegrino, P., Williams, I., Cohen, M.S., Gao, F., *et al.* (2013). Relative resistance of HIV-1
1226 founder viruses to control by interferon-alpha. *Retrovirology* 10, 146.

1227 Foley, E.A., Maldonado, M., and Kapoor, T.M. (2011). Formation of stable attachments
1228 between kinetochores and microtubules depends on the B56-PP2A phosphatase. *Nature*
1229 *cell biology* 13, 1265-1271.

1230 Foley, G.E., Handler, A.H., Lynch, P.M., Wolman, S.R., Stulberg, C.S., and Eagle, H. (1965).
1231 Loss of neoplastic properties in vitro. II. Observations on KB sublines. *Cancer Res* 25, 1254-
1232 1261.

1233 Gabuzda, D.H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W.A.,
1234 and Sodroski, J. (1992). Role of vif in replication of human immunodeficiency virus type 1 in
1235 CD4+ T lymphocytes. *J Virol* 66, 6489-6495.

1236 Gaddis, N.C., Chertova, E., Sheehy, A.M., Henderson, L.E., and Malim, M.H. (2003).
1237 Comprehensive investigation of the molecular defect in vif-deficient human
1238 immunodeficiency virus type 1 virions. *J Virol* 77, 5810-5820.

1239 Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012). Comparative proteomic
1240 analysis of eleven common cell lines reveals ubiquitous but varying expression of most
1241 proteins. *Mol Cell Proteomics* 11, M111 014050.

1242 Goh, W.C., Rogel, M.E., Kinsey, C.M., Michael, S.F., Fultz, P.N., Nowak, M.A., Hahn, B.H.,
1243 and Emerman, M. (1998). HIV-1 Vpr increases viral expression by manipulation of the cell
1244 cycle: a mechanism for selection of Vpr in vivo. *Nat Med* 4, 65-71.

1245 Grallert, A., Boke, E., Hagting, A., Hodgson, B., Connolly, Y., Griffiths, J.R., Smith, D.L.,
1246 Pines, J., and Hagan, I.M. (2015). A PP1-PP2A phosphatase relay controls mitotic
1247 progression. *Nature* 517, 94-98.

1248 Greenwood, E.J., Matheson, N.J., Wals, K., van den Boomen, D.J., Antrobus, R.,
1249 Williamson, J.C., and Lehner, P.J. (2016). Temporal proteomic analysis of HIV infection
1250 reveals remodelling of the host phosphoproteome by lentiviral Vif variants. *Elife* 5.

1251 Greenwood, E.J.D., Williamson, J.C., Sienkiewicz, A., Naamati, A., Matheson, N.J., and
1252 Lehner, P.J. (2019). Promiscuous Targeting of Cellular Proteins by Vpr Drives Systems-
1253 Level Proteomic Remodeling in HIV-1 Infection. *Cell Rep* 27, 1579-1596 e1577.

1254 Gummuluru, S., and Emerman, M. (1999). Cell cycle- and Vpr-mediated regulation of human
1255 immunodeficiency virus type 1 expression in primary and transformed T-cell lines. *J Virol* 73,
1256 5422-5430.

1257 Guo, Y., Dong, L., Qiu, X., Wang, Y., Zhang, B., Liu, H., Yu, Y., Zang, Y., Yang, M., and
1258 Huang, Z. (2014). Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by
1259 HIV-1 Vif. *Nature* 505, 229-233.

1260 Guy, B., Kieny, M.P., Riviere, Y., Le Peuch, C., Dott, K., Girard, M., Montagnier, L., and
 1261 Lecocq, J.P. (1987). HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling
 1262 an oncogene product. *Nature* 330, 266-269.

1263 Harris, R.S., and Anderson, B.D. (2016). Evolutionary Paradigms from Ancient and Ongoing
 1264 Conflicts between the Lentiviral Vif Protein and Mammalian APOBEC3 Enzymes. *PLOS*
 1265 *Pathogens* 12, e1005958.

1266 He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D.O., and Landau, N.R. (1995). Human
 1267 immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell
 1268 cycle by inhibiting p34cdc2 activity. *J Virol* 69, 6705-6711.

1269 He, Z., Zhang, W., Chen, G., Xu, R., and Yu, X.-F. (2008). Characterization of Conserved
 1270 Motifs in HIV-1 Vif Required for APOBEC3G and APOBEC3F Interaction. 381, 1000-1011.

1271 Hertz, E.P.T., Kruse, T., Davey, N.E., Lopez-Mendez, B., Sigurethsson, J.O., Montoya, G.,
 1272 Olsen, J.V., and Nilsson, J. (2016). A Conserved Motif Provides Binding Specificity to the
 1273 PP2A-B56 Phosphatase. *Mol Cell* 63, 686-695.

1274 Hultquist, J.F., Lengyel, J.A., Refsland, E.W., LaRue, R.S., Lackey, L., Brown, W.L., and
 1275 Harris, R.S. (2011). Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and
 1276 APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. *J Virol* 85,
 1277 11220-11234.

1278 Iwabu, Y., Kinomoto, M., Tatsumi, M., Fujita, H., Shimura, M., Tanaka, Y., Ishizaka, Y.,
 1279 Nolan, D., Mallal, S., Sata, T., *et al.* (2010). Differential anti-APOBEC3G activity of HIV-1 Vif
 1280 proteins derived from different subtypes. *J Biol Chem* 285, 35350-35358.

1281 Izumi, T., Ito, K., Matsui, M., Shirakawa, K., Shinohara, M., Nagai, Y., Kawahara, M.,
 1282 Kobayashi, M., Kondoh, H., Misawa, N., *et al.* (2010). HIV-1 viral infectivity factor interacts
 1283 with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. *Proc Natl*
 1284 *Acad Sci U S A* 107, 20798-20803.

1285 Jowett, J.B., Planelles, V., Poon, B., Shah, N.P., Chen, M.L., and Chen, I.S. (1995). The
 1286 human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase
 1287 of the cell cycle. *J Virol* 69, 6304-6313.

1288 Kobayashi, M., Takaori-Kondo, A., Miyauchi, Y., Iwai, K., and Uchiyama, T. (2005).
1289 Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is
1290 essential for Vif function. *J Biol Chem* 280, 18573-18578.

1291 Koning, F.A., Newman, E.N., Kim, E.Y., Kunstman, K.J., Wolinsky, S.M., and Malim, M.H.
1292 (2009). Defining APOBEC3 expression patterns in human tissues and hematopoietic cell
1293 subsets. *J Virol* 83, 9474-9485.

1294 Laguette, N., Bregnard, C., Hue, P., Basbous, J., Yatim, A., Larroque, M., Kirchhoff, F.,
1295 Constantinou, A., Sobhian, B., and Benkirane, M. (2014). Premature activation of the SLX4
1296 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. *Cell* 156,
1297 134-145.

1298 Lee, S.J., Rodriguez-Bravo, V., Kim, H., Datta, S., and Foley, E.A. (2017). The PP2A(B56)
1299 phosphatase promotes the association of Cdc20 with APC/C in mitosis. *J Cell Sci* 130, 1760-
1300 1771.

1301 Letko, M., Booiman, T., Kootstra, N., Simon, V., and Ooms, M. (2015). Identification of the
1302 HIV-1 Vif and Human APOBEC3G Protein Interface. *Cell Reports* 13, 1789-1799.

1303 Li, X., Scuderi, A., Letsou, A., and Virshup, D.M. (2002). B56-associated protein
1304 phosphatase 2A is required for survival and protects from apoptosis in *Drosophila*
1305 *melanogaster*. *Mol Cell Biol* 22, 3674-3684.

1306 Liu, M.K., Hawkins, N., Ritchie, A.J., Ganusov, V.V., Whale, V., Brackenridge, S., Li, H.,
1307 Pavlicek, J.W., Cai, F., Rose-Abrahams, M., *et al.* (2013). Vertical T cell immunodominance
1308 and epitope entropy determine HIV-1 escape. *J Clin Invest* 123, 380-393.

1309 Madsen, J.M., and Stoltzfus, C.M. (2005). An exonic splicing silencer downstream of the 3'
1310 splice site A2 is required for efficient human immunodeficiency virus type 1 replication. *J*
1311 *Virol* 79, 10478-10486.

1312 Marin, M., Rose, K.M., Kozak, S.L., and Kabat, D. (2003). HIV-1 Vif protein binds the editing
1313 enzyme APOBEC3G and induces its degradation. *Nat Med* 9, 1398-1403.

1314 Matheson, N.J., Peden, A.A., and Lehner, P.J. (2014). Antibody-free magnetic cell sorting of
 1315 genetically modified primary human CD4+ T cells by one-step streptavidin affinity
 1316 purification. *PLoS One* 9, e111437.

1317 Matheson, N.J., Sumner, J., Wals, K., Rapiteanu, R., Weekes, M.P., Vigan, R., Weinelt, J.,
 1318 Schindler, M., Antrobus, R., Costa, A.S., *et al.* (2015). Cell Surface Proteomic Map of HIV
 1319 Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. *Cell Host Microbe*
 1320 18, 409-423.

1321 Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2004). Vif
 1322 overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the
 1323 ubiquitin-proteasome pathway. *J Biol Chem* 279, 7792-7798.

1324 Mehle, A., Wilson, H., Zhang, C., Brazier, A.J., McPike, M., Pery, E., and Gabuzda, D.
 1325 (2007). Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type
 1326 1 Vif and Inhibitors of Vif-APOBEC3G Binding. *J Virol* 81, 13235-13241.

1327 Menzies, S.A., Volkmar, N., van den Boomen, D.J., Timms, R.T., Dickson, A.S., Nathan,
 1328 J.A., and Lehner, P.J. (2018). The sterol-responsive RNF145 E3 ubiquitin ligase mediates
 1329 the degradation of HMG-CoA reductase together with gp78 and Hrd1. *Elife* 7.

1330 Miles, A.L., Burr, S.P., Grice, G.L., and Nathan, J.A. (2017). The vacuolar-ATPase complex
 1331 and assembly factors, TMEM199 and CCDC115, control HIF1alpha prolyl hydroxylation by
 1332 regulating cellular iron levels. *Elife* 6.

1333 Mulder, L.C., Harari, A., and Simon, V. (2008). Cytidine deamination induced HIV-1 drug
 1334 resistance. *Proc Natl Acad Sci U S A* 105, 5501-5506.

1335 Naamati, A., Williamson, J.C., Greenwood, E.J., Marelli, S., Lehner, P.J., and Matheson,
 1336 N.J. (2019). Functional proteomic atlas of HIV infection in primary human CD4+ T cells. *Elife*
 1337 8.

1338 Nakano, Y., Aso, H., Soper, A., Yamada, E., Moriwaki, M., Juarez-Fernandez, G., Koyanagi,
 1339 Y., and Sato, K. (2017). A conflict of interest: the evolutionary arms race between
 1340 mammalian APOBEC3 and lentiviral Vif. *Retrovirology* 14, 31.

1341 Nakashima, M., Ode, H., Kawamura, T., Kitamura, S., Naganawa, Y., Awazu, H., Tsuzuki,
 1342 S., Matsuoka, K., Nemoto, M., Hachiya, A., *et al.* (2016). Structural Insights into HIV-1 Vif-
 1343 APOBEC3F Interaction. *90*, 1034-1047.
 1344 Nasa, I., and Kettenbach, A.N. (2018). Coordination of Protein Kinase and Phosphoprotein
 1345 Phosphatase Activities in Mitosis. *Front Cell Dev Biol* 6, 30.
 1346 Ooms, M., Letko, M., Binka, M., and Simon, V. (2013). The resistance of human APOBEC3H
 1347 to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. *PLoS One* 8,
 1348 e57744.
 1349 Ooms, M., Letko, M., and Simon, V. (2016). The structural interface between HIV-1 Vif and
 1350 human APOBEC3H. *JVI.02289-02216*.
 1351 Parrish, N.F., Gao, F., Li, H., Giorgi, E.E., Barbian, H.J., Parrish, E.H., Zajic, L., Iyer, S.S.,
 1352 Decker, J.M., Kumar, A., *et al.* (2013). Phenotypic properties of transmitted founder HIV-1.
 1353 *Proc Natl Acad Sci U S A* 110, 6626-6633.
 1354 Peng, G., Greenwell-Wild, T., Nares, S., Jin, W., Lei, K.J., Rangel, Z.G., Munson, P.J., and
 1355 Wahl, S.M. (2007). Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3
 1356 expression. *Blood* 110, 393-400.
 1357 R Core Team (2019). R: A language and environment for statistical computing (Vienna,
 1358 Austria: R Foundation for Statistical Computing).
 1359 Refsland, E.W., Stenglein, M.D., Shindo, K., Albin, J.S., Brown, W.L., and Harris, R.S.
 1360 (2010). Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and
 1361 tissues: implications for HIV-1 restriction. *Nucleic Acids Res* 38, 4274-4284.
 1362 Richards, C., John, Demir, Ö., Nadine, Elizabeth, Allison, Brett, John, John, Daniel, *et al.*
 1363 (2015). The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by
 1364 Genetic and Computational Approaches. *Cell Reports* 13, 1781-1788.
 1365 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015).
 1366 limma powers differential expression analyses for RNA-sequencing and microarray studies.
 1367 *Nucleic Acids Res* 43, e47.

1368 Rogel, M.E., Wu, L.I., and Emerman, M. (1995). The human immunodeficiency virus type 1
1369 vpr gene prevents cell proliferation during chronic infection. *J Virol* 69, 882-888.

1370 Russell, R.A., and Pathak, V.K. (2007). Identification of Two Distinct Human
1371 Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human
1372 APOBEC3G and APOBEC3F. *J Virol* 81, 8201-8210.

1373 Sakai, K., Dimas, J., and Lenardo, M.J. (2006). The Vif and Vpr accessory proteins
1374 independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. *Proc Natl Acad*
1375 *Sci U S A* 103, 3369-3374.

1376 Schwammle, V., Leon, I.R., and Jensen, O.N. (2013). Assessment and improvement of
1377 statistical tools for comparative proteomics analysis of sparse data sets with few
1378 experimental replicates. *J Proteome Res* 12, 3874-3883.

1379 Sheehy, A.M., Gaddis, N.C., Choi, J.D., and Malim, M.H. (2002). Isolation of a human gene
1380 that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* 418, 646-650.

1381 Sheehy, A.M., Gaddis, N.C., and Malim, M.H. (2003). The antiretroviral enzyme APOBEC3G
1382 is degraded by the proteasome in response to HIV-1 Vif. *Nat Med* 9, 1404-1407.

1383 Sievers, F., and Higgins, D.G. (2014). Clustal Omega, accurate alignment of very large
1384 numbers of sequences. *Methods Mol Biol* 1079, 105-116.

1385 Simon, J.H., Southerling, T.E., Peterson, J.C., Meyer, B.E., and Malim, M.H. (1995).
1386 Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not
1387 nonprimate, lentivirus vif genes. *J Virol* 69, 4166-4172.

1388 Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D.D., and Bieniasz, P.D. (2005a). Natural
1389 Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1
1390 Diversification. *PLoS Pathogens* 1, e6.

1391 Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D.D., and Bieniasz, P.D. (2005b). Natural
1392 variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1
1393 diversification. *PLoS Pathog* 1, e6.

1394 Stopak, K., de Noronha, C., Yonemoto, W., and Greene, W.C. (2003). HIV-1 Vif blocks the
1395 antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. *Mol*
1396 *Cell* 12, 591-601.

1397 Swingle, M., Ni, L., and Honkanen, R.E. (2007). Small-molecule inhibitors of ser/thr protein
1398 phosphatases: specificity, use and common forms of abuse. *Methods Mol Biol* 365, 23-38.

1399 Vallardi, G., Allan, L.A., Crozier, L., and Saurin, A.T. (2019). Division of labour between
1400 PP2A-B56 isoforms at the centromere and kinetochore. *Elife* 8.

1401 van den Boomen, D.J., Timms, R.T., Grice, G.L., Stagg, H.R., Skodt, K., Dougan, G.,
1402 Nathan, J.A., and Lehner, P.J. (2014). TMEM129 is a Derlin-1 associated ERAD E3 ligase
1403 essential for virus-induced degradation of MHC-I. *Proc Natl Acad Sci U S A* 111, 11425-
1404 11430.

1405 Wang, J., Shackelford, J.M., Casella, C.R., Shivers, D.K., Rapaport, E.L., Liu, B., Yu, X.F.,
1406 and Finkel, T.H. (2007). The Vif accessory protein alters the cell cycle of human
1407 immunodeficiency virus type 1 infected cells. *Virology* 359, 243-252.

1408 Wang, J., Wang, Z., Yu, T., Yang, H., Virshup, D.M., Kops, G.J., Lee, S.H., Zhou, W., Li, X.,
1409 Xu, W., *et al.* (2016). Crystal structure of a PP2A B56-BubR1 complex and its implications
1410 for PP2A substrate recruitment and localization. *Protein Cell* 7, 516-526.

1411 Wang, Q., and Lee, C. (2007). Distinguishing Functional Amino Acid Covariation from
1412 Background Linkage Disequilibrium in HIV Protease and Reverse Transcriptase. *Plos One* 2.

1413 Wickham, H. (2009). *Ggplot2 : elegant graphics for data analysis* (New York: Springer).

1414 Willey, R.L., Maldarelli, F., Martin, M.A., and Strebel, K. (1992). Human immunodeficiency
1415 virus type 1 Vpu protein induces rapid degradation of CD4. *J Virol* 66, 7193-7200.

1416 Wlodarchak, N., and Xing, Y. (2016). PP2A as a master regulator of the cell cycle. *Crit Rev*
1417 *Biochem Mol Biol* 51, 162-184.

1418 Wu, L., Martin, T.D., Carrington, M., and KewalRamani, V.N. (2004). Raji B cells,
1419 misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. *Virology* 318,
1420 17-23.

1421 Yamashita, T., Kamada, K., Hatcho, K., Adachi, A., and Nomaguchi, M. (2008). Identification
1422 of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
1423 *Microbes Infect* 10, 1142-1149.

1424 Yang, J., and Phiel, C. (2010). Functions of B56-containing PP2As in major developmental
1425 and cancer signaling pathways. *Life sciences* 87, 659-666.

1426 Yu, G.C., Lam, T.T.Y., Zhu, H.C., and Guan, Y. (2018). Two Methods for Mapping and
1427 Visualizing Associated Data on Phylogeny Using Ggtree. *Molecular biology and evolution*
1428 35, 3041-3043.

1429 Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X.F. (2003). Induction of
1430 APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. *Science*
1431 302, 1056-1060.

1432 Zhao, K., Du, J., Rui, Y., Zheng, W., Kang, J., Hou, J., Wang, K., Zhang, W., Simon, V.A.,
1433 and Yu, X.F. (2015). Evolutionarily conserved pressure for the existence of distinct G2/M cell
1434 cycle arrest and A3H inactivation functions in HIV-1 Vif. *Cell cycle* 14, 838-847.

1435

Figure 1

A

B

C

D

E

Figure 2

A

B

C

D

Figure 3

Figure 4

Figure 5

A

B

D

C

Figure 6

A

D

B

C

Figure 7

Figure 1–figure supplement 1

A

B

293T cells stably expressing
HA-tagged PPP2R5B or APOBEC3G

Transfect with
GFP-P2A-Vif
mutant library

Analyse by intracellular
flow cytometry

C

Figure 1–figure supplement 2

A

B

C

Figure 1–figure supplement 3

Figure 1–figure supplement 4

Figure 2—figure supplement 1

Figure 2–figure supplement 2

Figure 3–figure supplement 1

Figure 3—figure supplement 2

Figure 4–figure supplement 1

Figure 4–figure supplement 2

A

C

B

D

E

Figure 4–figure supplement 3

Figure 5—figure supplement 1

Figure 5—figure supplement 2

Figure 6–figure supplement 1

Figure 6–figure supplement 2

Figure 6–figure supplement 3

A

B

Figure 7–figure supplement 1

A

B

Figure 7–figure supplement 2

A

B

Figure 7–figure supplement 3

A

B

C

Figure 7–figure supplement 4

A

B